data_2lzs_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lzs _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' FME . . . . . 0.514 ' SD ' ' N ' ' A' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.16 175.51 44.13 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 82.83 14.07 76.3 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.3 tt -136.21 149.66 27.52 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.78 0.324 . . . . 0.0 110.474 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.411 ' O ' ' OE1' ' A' ' 8' ' ' GLN . 0.4 OUTLIER 49.37 18.85 0.29 Allowed 'General case' 0 C--O 1.222 -0.346 0 CA-C-O 120.946 0.403 . . . . 0.0 110.276 -179.59 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.6 pt -49.49 -32.15 6.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-O 121.164 0.507 . . . . 0.0 109.796 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.537 ' CH2' ' O ' ' I' ' 5' ' ' SER . 35.5 m95 -60.44 -28.91 68.66 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.443 -179.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.411 ' OE1' ' O ' ' A' ' 5' ' ' SER . 9.7 mp0 -60.03 -34.52 73.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.025 0.44 . . . . 0.0 110.328 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.8 tt -69.9 -38.57 76.36 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.454 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.1 mp -60.69 -47.44 86.26 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.773 -179.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.4 tt -64.89 -43.59 96.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.171 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 34.1 mt -63.68 -44.21 98.35 Favored 'Isoleucine or valine' 0 C--N 1.343 0.296 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.667 179.112 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.82 -39.96 90.98 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.239 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 41.8 t -60.22 -44.82 96.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 C-N-CA 120.69 -0.404 . . . . 0.0 109.967 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.401 HD11 HG23 ' A' ' 15' ' ' ILE . 28.8 mt -61.28 -44.52 98.58 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.574 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.198 179.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.1 t -58.86 -45.4 91.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.498 -0.481 . . . . 0.0 110.853 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.573 ' O ' ' N ' ' A' ' 21' ' ' GLY . 77.1 t -63.36 -43.08 98.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.876 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 46.5 mt -65.08 -46.64 80.3 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 121.722 -0.611 . . . . 0.0 110.854 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 77.6 mt -63.65 -42.22 98.12 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.546 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -89.16 -10.74 46.06 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.312 179.235 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.573 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 73.82 176.72 34.31 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.091 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.5 t -102.02 -39.17 7.44 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 117.752 0.776 . . . . 0.0 111.043 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -63.84 -46.47 84.9 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.835 179.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -64.46 -41.93 96.23 Favored 'General case' 0 C--O 1.227 -0.119 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.081 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 6.8 tt -60.61 -22.81 64.17 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.939 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.73 -51.73 33.79 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 77.9 p -62.89 -41.48 99.43 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.753 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 96.7 mt -62.78 -47.43 92.91 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.746 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.406 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -64.07 -50.97 57.02 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.238 -0.982 . . . . 0.0 111.437 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.4 m -60.66 -38.21 84.12 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 117.207 0.503 . . . . 0.0 110.403 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -63.75 -43.46 96.38 Favored 'General case' 0 C--N 1.33 -0.26 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.297 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 66.9 mt -84.59 -12.05 54.82 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.261 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -85.19 6.98 77.58 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 120.657 -0.783 . . . . 0.0 111.268 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.72 -37.33 87.24 Favored 'General case' 0 C--N 1.331 -0.21 0 O-C-N 122.444 -0.445 . . . . 0.0 110.778 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 68.7 p -65.7 -36.68 84.33 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-O 120.907 0.384 . . . . 0.0 110.782 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 90.4 mt -61.36 -40.88 87.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.072 179.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -55.84 -37.6 68.94 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 120.511 -0.476 . . . . 0.0 109.836 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.72 -41.87 81.82 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.764 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.484 ' O ' ' SD ' ' A' ' 43' ' ' MET . 7.6 m-85 -60.83 -46.78 89.23 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 119.936 -0.706 . . . . 0.0 109.549 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -58.57 -46.14 87.53 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.071 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -61.68 -51.04 70.08 Favored 'General case' 0 N--CA 1.457 -0.124 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.407 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.41 ' C ' ' H ' ' A' ' 44' ' ' SER . . . -57.59 -43.91 84.97 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.313 -179.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.531 ' N ' ' SD ' ' A' ' 43' ' ' MET . 0.0 OUTLIER -77.24 17.09 0.5 Allowed 'General case' 0 CA--C 1.531 0.223 0 O-C-N 122.206 -0.308 . . . . 0.0 110.224 179.981 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.41 ' H ' ' C ' ' A' ' 42' ' ' ALA . 78.5 p -71.54 -15.53 62.29 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 120.823 0.344 . . . . 0.0 110.475 178.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 36.2 p-10 -60.96 -42.18 97.77 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.019 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.519 ' N ' ' OD1' ' A' ' 45' ' ' ASP . 92.4 m-20 -109.28 52.3 0.72 Allowed 'General case' 0 N--CA 1.469 0.483 0 O-C-N 122.461 -0.149 . . . . 0.0 110.806 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -175.89 96.14 0.26 Allowed Pre-proline 0 CA--C 1.535 0.388 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -76.25 150.38 32.88 Favored 'Trans proline' 0 N--CA 1.491 1.326 0 C-N-CA 121.787 1.658 . . . . 0.0 112.078 -179.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 98.9 mttt . . . . . 0 N--CA 1.464 0.238 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.458 -179.954 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' FME . . . . . 0.593 ' N ' ' SD ' ' B' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.0 98.22 0.13 Allowed Glycine 0 CA--C 1.526 0.734 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -64.66 -39.21 96.54 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' ILE . . . . . . . . . . . . . 80.0 mt -68.86 86.1 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 40.1 t -117.59 124.16 47.98 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 121.227 0.537 . . . . 0.0 111.313 -179.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' ILE . . . . . . . . . . . . . 16.7 tt -67.64 -32.53 57.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.373 -0.831 . . . . 0.0 109.389 178.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' TRP . . . . . . . . . . . . . 48.4 m95 -62.61 -28.79 70.14 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.564 -178.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' GLN . . . . . . . . . . . . . 56.7 mm-40 -60.08 -34.99 74.2 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 96.8 mt -69.41 -38.58 77.99 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.629 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 2.2 mt -61.14 -47.55 85.73 Favored 'General case' 0 N--CA 1.468 0.455 0 O-C-N 121.788 -0.57 . . . . 0.0 110.361 -179.051 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' ILE . . . . . . . . . . . . . 9.5 tt -65.01 -43.46 96.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.049 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 52.3 mt -63.77 -43.62 98.02 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.933 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.19 -39.98 92.21 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.74 -0.384 . . . . 0.0 110.118 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 51.1 t -60.07 -45.01 96.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.468 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 55.3 mt -60.89 -44.75 98.48 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.615 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.321 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' VAL . . . . . . . . . . . . . 48.9 t -58.88 -45.44 91.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.757 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' VAL . . . . . 0.566 ' O ' ' N ' ' B' ' 21' ' ' GLY . 95.2 t -63.52 -42.9 97.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.719 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' LEU . . . . . . . . . . . . . 4.5 mt -65.31 -46.15 81.5 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 119.904 -0.718 . . . . 0.0 111.13 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.468 ' HG ' ' O ' ' B' ' 15' ' ' ILE . 51.7 mt -63.89 -42.11 97.54 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.517 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -88.85 -10.89 46.38 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 110.299 -0.26 . . . . 0.0 110.299 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' B' ' 17' ' ' VAL . . . 73.63 176.57 33.34 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 -178.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.02 -38.78 7.61 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 117.291 0.545 . . . . 0.0 111.152 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -63.82 -46.5 84.82 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.323 -0.551 . . . . 0.0 110.94 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' LYS . . . . . . . . . . . . . 41.7 tptt -64.54 -41.88 96.07 Favored 'General case' 0 N--CA 1.455 -0.221 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 7.3 tt -60.33 -22.89 63.75 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.09 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.89 -51.37 35.13 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 120.197 -1.001 . . . . 0.0 110.674 -179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' SER . . . . . . . . . . . . . 45.2 t -62.95 -41.67 99.59 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.68 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' ILE . . . . . . . . . . . . . 95.4 mt -63.18 -46.68 95.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 120.529 -0.468 . . . . 0.0 110.794 -179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.02 -51.19 55.28 Favored Glycine 0 CA--C 1.526 0.755 0 C-N-CA 120.6 -0.81 . . . . 0.0 111.418 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' SER . . . . . . . . . . . . . 20.0 m -60.64 -38.4 84.68 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 117.09 0.445 . . . . 0.0 110.349 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -63.81 -43.46 96.19 Favored 'General case' 0 C--N 1.331 -0.208 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.168 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 76.7 mt -84.51 -11.83 55.38 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.213 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -85.43 6.86 78.6 Favored Glycine 0 CA--C 1.531 1.059 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.224 -179.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.58 -37.24 86.87 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 120.48 -0.488 . . . . 0.0 110.999 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' SER . . . . . . . . . . . . . 66.4 p -65.83 -36.67 84.11 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.508 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' ILE . . . . . . . . . . . . . 87.5 mt -61.4 -41.24 89.14 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -55.65 -37.73 68.63 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.826 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.73 -42.12 80.84 Favored Glycine 0 CA--C 1.527 0.794 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.514 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -60.11 -47.12 87.21 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 120.212 -0.595 . . . . 0.0 109.826 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 46.2 tptt -58.98 -45.9 89.44 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.857 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' LYS . . . . . . . . . . . . . 45.2 mmtt -61.52 -51.19 69.66 Favored 'General case' 0 C--O 1.227 -0.087 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.374 -179.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.78 -43.71 85.76 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 120.008 -0.677 . . . . 0.0 111.254 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' MET . . . . . . . . . . . . . 2.4 mpp? -77.27 14.0 1.03 Allowed 'General case' 0 C--N 1.331 -0.196 0 O-C-N 122.185 -0.322 . . . . 0.0 110.372 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' SER . . . . . . . . . . . . . 57.7 m -153.66 38.81 0.48 Allowed 'General case' 0 N--CA 1.462 0.169 0 CA-C-O 120.753 0.311 . . . . 0.0 110.75 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -61.4 -42.82 99.33 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.27 -0.423 . . . . 0.0 109.88 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -81.94 44.61 0.85 Allowed 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 121.306 0.574 . . . . 0.0 110.395 179.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' GLU . . . . . . . . . . . . . 30.2 tp10 -171.74 88.21 0.45 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.487 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_exo -62.13 147.86 94.28 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 C-N-CA 122.436 2.091 . . . . 0.0 112.059 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt . . . . . 0 N--CA 1.467 0.385 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.297 -179.853 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 2' ' ' GLY . . . . . . . . . . . . . . . 57.93 -112.18 3.64 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -66.82 -176.19 7.57 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 4' ' ' ILE . . . . . . . . . . . . . 80.5 mt 55.38 79.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 5' ' ' SER . . . . . . . . . . . . . 45.4 t -119.8 125.87 49.63 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 121.419 0.628 . . . . 0.0 112.545 -179.026 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 tt -66.3 -32.82 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.271 -0.877 . . . . 0.0 108.744 177.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 7' ' ' TRP . . . . . . . . . . . . . 44.5 m95 -57.14 -28.85 63.1 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.414 -1.267 . . . . 0.0 110.625 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 8' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -59.61 -35.07 73.61 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.854 0.359 . . . . 0.0 110.303 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 9' ' ' LEU . . . . . . . . . . . . . 80.9 mt -69.51 -38.52 77.61 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.771 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 10' ' ' LEU . . . . . . . . . . . . . 3.0 mt -61.05 -47.41 86.48 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.613 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 11' ' ' ILE . . . . . . . . . . . . . 13.2 tt -65.12 -43.22 95.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 120.441 -0.503 . . . . 0.0 110.192 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 12' ' ' ILE . . . . . . . . . . . . . 69.2 mt -63.69 -44.25 98.35 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.498 178.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.97 -40.11 92.17 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 14' ' ' VAL . . . . . . . . . . . . . 25.5 t -59.93 -45.2 95.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 C-N-CA 120.723 -0.391 . . . . 0.0 109.977 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 15' ' ' ILE . . . . . 0.503 ' O ' ' HG ' ' C' ' 19' ' ' LEU . 70.1 mt -60.8 -44.89 98.48 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.722 0 C-N-CA 120.424 -0.511 . . . . 0.0 110.238 179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 16' ' ' VAL . . . . . . . . . . . . . 25.5 t -58.74 -45.46 91.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.94 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 17' ' ' VAL . . . . . 0.583 ' O ' ' N ' ' C' ' 21' ' ' GLY . 71.1 t -63.27 -43.06 98.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 C-N-CA 120.91 -0.316 . . . . 0.0 110.933 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 18' ' ' LEU . . . . . . . . . . . . . 79.9 mt -65.22 -46.19 81.64 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.953 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 19' ' ' LEU . . . . . 0.503 ' HG ' ' O ' ' C' ' 15' ' ' ILE . 45.1 mt -63.83 -42.36 97.66 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.288 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -88.91 -10.78 46.59 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 120.652 0.263 . . . . 0.0 110.317 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 21' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' C' ' 17' ' ' VAL . . . 73.64 176.54 33.33 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -178.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 22' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.0 -38.79 7.61 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 117.333 0.567 . . . . 0.0 111.168 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 23' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -63.88 -46.76 83.47 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.801 179.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 24' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -64.36 -41.85 96.51 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.896 0.379 . . . . 0.0 110.122 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 25' ' ' LEU . . . . . . . . . . . . . 7.3 tt -60.46 -23.05 64.14 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.93 179.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.89 -51.34 35.26 Favored Glycine 0 C--N 1.334 0.451 0 C-N-CA 120.208 -0.996 . . . . 0.0 110.683 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 27' ' ' SER . . . . . . . . . . . . . 77.8 p -62.86 -41.69 99.47 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 121.141 -0.223 . . . . 0.0 110.664 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 28' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.94 -47.0 94.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 C-N-CA 120.469 -0.492 . . . . 0.0 110.632 -179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.406 ' O ' ' N ' ' C' ' 33' ' ' GLY . . . -64.34 -50.87 57.15 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.173 -179.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 30' ' ' SER . . . . . . . . . . . . . 24.8 m -60.62 -38.51 84.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 117.332 0.566 . . . . 0.0 110.404 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 31' ' ' ASP . . . . . . . . . . . . . 75.2 m-20 -63.67 -43.65 96.08 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.114 179.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 32' ' ' LEU . . . . . . . . . . . . . 73.3 mt -84.48 -11.86 55.37 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.362 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' C' ' 29' ' ' GLY . . . -85.14 6.55 79.01 Favored Glycine 0 CA--C 1.528 0.844 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.41 -37.43 87.48 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.735 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 35' ' ' SER . . . . . . . . . . . . . 15.5 m -65.63 -36.79 84.73 Favored 'General case' 0 C--O 1.22 -0.482 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.837 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 87.1 mt -61.3 -41.09 88.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.049 179.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 37' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -55.51 -37.72 68.25 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.834 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.86 -42.03 80.27 Favored Glycine 0 CA--C 1.523 0.584 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.597 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 39' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -60.62 -46.89 88.59 Favored 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 119.93 -0.708 . . . . 0.0 109.715 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 40' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -58.68 -45.86 88.53 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.059 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 41' ' ' LYS . . . . . . . . . . . . . 40.2 tttp -61.87 -50.96 70.14 Favored 'General case' 0 C--O 1.224 -0.273 0 CA-C-N 116.532 -0.303 . . . . 0.0 111.363 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.71 -43.98 85.59 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 120.056 -0.658 . . . . 0.0 111.237 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 43' ' ' MET . . . . . . . . . . . . . 33.8 ttm -77.21 14.39 0.93 Allowed 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.472 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 44' ' ' SER . . . . . . . . . . . . . 12.7 p -134.01 -28.96 1.32 Allowed 'General case' 0 N--CA 1.47 0.543 0 O-C-N 121.755 -0.59 . . . . 0.0 110.952 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 45' ' ' ASP . . . . . 0.415 ' O ' ' OD1' ' C' ' 46' ' ' ASP . 31.0 t70 -59.32 -48.26 82.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.758 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 46' ' ' ASP . . . . . 0.415 ' OD1' ' O ' ' C' ' 45' ' ' ASP . 5.8 p-10 39.0 54.94 2.09 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.616 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 47' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -170.1 87.75 0.55 Allowed Pre-proline 0 N--CA 1.465 0.322 0 N-CA-C 110.414 -0.217 . . . . 0.0 110.414 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 48' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -76.52 157.0 36.51 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.852 1.701 . . . . 0.0 112.321 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 49' ' ' LYS . . . . . . . . . . . . . 54.0 mttp . . . . . 0 C--N 1.332 -0.164 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.43 179.994 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 2' ' ' GLY . . . . . . . . . . . . . . . -64.2 145.51 49.69 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.799 -0.921 . . . . 0.0 110.799 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -82.9 -71.48 1.31 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 4' ' ' ILE . . . . . . . . . . . . . 75.8 mt 40.5 77.72 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-O 120.835 0.35 . . . . 0.0 110.138 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 5' ' ' SER . . . . . 0.455 ' OG ' ' OE1' ' D' ' 8' ' ' GLN . 4.1 t -114.78 131.42 56.8 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.632 0.729 . . . . 0.0 111.571 -178.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 6' ' ' ILE . . . . . . . . . . . . . 5.2 tt -66.03 -25.35 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.308 179.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 7' ' ' TRP . . . . . . . . . . . . . 34.9 m95 -62.07 -28.87 69.91 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 117.023 -1.871 . . . . 0.0 110.635 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 8' ' ' GLN . . . . . 0.646 ' N ' ' OE1' ' D' ' 8' ' ' GLN . 6.8 mp0 -60.12 -34.71 73.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.069 0.462 . . . . 0.0 110.178 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 9' ' ' LEU . . . . . . . . . . . . . 5.0 tt -69.65 -38.63 77.21 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.513 179.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 10' ' ' LEU . . . . . . . . . . . . . 3.8 mt -61.02 -47.16 87.71 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 120.446 -0.502 . . . . 0.0 110.721 -179.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 11' ' ' ILE . . . . . . . . . . . . . 11.0 tt -65.11 -43.32 95.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.001 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 12' ' ' ILE . . . . . . . . . . . . . 44.1 mt -63.73 -44.14 98.23 Favored 'Isoleucine or valine' 0 C--N 1.338 0.09 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.918 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.62 -40.26 91.25 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.27 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 14' ' ' VAL . . . . . 0.58 ' O ' ' HG ' ' D' ' 18' ' ' LEU . 36.0 t -60.02 -44.81 95.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.932 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 15' ' ' ILE . . . . . 0.428 HD11 HG22 ' D' ' 15' ' ' ILE . 38.8 mt -61.19 -44.79 99.05 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.84 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.169 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 16' ' ' VAL . . . . . . . . . . . . . 55.9 t -58.63 -45.48 90.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 C-N-CA 120.543 -0.463 . . . . 0.0 111.004 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 17' ' ' VAL . . . . . 0.575 ' O ' ' N ' ' D' ' 21' ' ' GLY . 74.1 t -63.27 -42.91 98.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 C-N-CA 120.779 -0.369 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 18' ' ' LEU . . . . . 0.58 ' HG ' ' O ' ' D' ' 14' ' ' VAL . 6.6 mt -65.45 -45.96 81.72 Favored 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 120.046 -0.662 . . . . 0.0 110.945 -179.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 19' ' ' LEU . . . . . 0.427 ' HG ' ' O ' ' D' ' 15' ' ' ILE . 56.4 mt -63.81 -42.44 97.67 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.298 -179.48 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -88.99 -10.8 46.27 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 120.718 0.294 . . . . 0.0 110.258 179.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 21' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' D' ' 17' ' ' VAL . . . 73.47 176.62 32.87 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -178.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 22' ' ' THR . . . . . . . . . . . . . 2.6 p -102.21 -38.71 7.56 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 117.466 0.633 . . . . 0.0 111.093 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 23' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -63.67 -46.66 84.56 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.925 179.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 24' ' ' LYS . . . . . . . . . . . . . 64.9 mttp -64.42 -42.1 96.22 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 25' ' ' LEU . . . . . . . . . . . . . 7.4 tt -60.33 -23.01 63.89 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 120.502 -0.479 . . . . 0.0 111.126 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.93 -51.31 35.28 Favored Glycine 0 C--N 1.338 0.655 0 C-N-CA 120.205 -0.998 . . . . 0.0 110.864 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 27' ' ' SER . . . . . . . . . . . . . 78.1 p -63.04 -41.19 99.45 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.758 179.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 28' ' ' ILE . . . . . . . . . . . . . 97.6 mt -63.27 -46.93 94.37 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.731 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' D' ' 33' ' ' GLY . . . -64.02 -51.09 56.12 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 120.48 -0.867 . . . . 0.0 111.236 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 30' ' ' SER . . . . . . . . . . . . . 17.8 m -60.8 -38.17 84.47 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 117.22 0.51 . . . . 0.0 110.438 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 31' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -63.76 -43.93 94.96 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 32' ' ' LEU . . . . . . . . . . . . . 80.2 mt -84.3 -11.88 55.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.528 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' D' ' 29' ' ' GLY . . . -85.04 6.46 79.13 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.37 -37.52 87.79 Favored 'General case' 0 N--CA 1.456 -0.138 0 CA-C-N 117.227 0.514 . . . . 0.0 110.776 -179.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 35' ' ' SER . . . . . . . . . . . . . 16.3 m -65.63 -36.58 84.11 Favored 'General case' 0 C--O 1.224 -0.26 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.926 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 36' ' ' ILE . . . . . . . . . . . . . 87.7 mt -61.46 -40.81 87.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.062 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 37' ' ' LYS . . . . . . . . . . . . . 53.1 mtpt -55.67 -37.79 68.76 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.89 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.82 -41.6 82.23 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.658 -0.782 . . . . 0.0 111.743 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 39' ' ' PHE . . . . . . . . . . . . . 7.4 m-85 -60.96 -46.57 90.19 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 120.037 -0.665 . . . . 0.0 109.82 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 40' ' ' LYS . . . . . . . . . . . . . 24.4 ttpp -58.73 -46.05 88.25 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.128 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 41' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -61.82 -50.98 70.11 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.253 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.64 -43.97 85.25 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 120.073 -0.651 . . . . 0.0 111.273 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 43' ' ' MET . . . . . 0.408 ' O ' ' OG ' ' D' ' 44' ' ' SER . 18.2 tpp -77.26 13.74 1.09 Allowed 'General case' 0 C--O 1.233 0.205 0 O-C-N 122.035 -0.415 . . . . 0.0 110.31 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 44' ' ' SER . . . . . 0.408 ' OG ' ' O ' ' D' ' 43' ' ' MET . 3.7 m -176.49 72.92 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.407 0 CA-C-O 120.74 0.305 . . . . 0.0 110.655 -179.336 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 45' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -61.34 -65.51 0.68 Allowed 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.721 -0.218 . . . . 0.0 111.188 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 46' ' ' ASP . . . . . 0.436 ' O ' ' CB ' ' D' ' 47' ' ' GLU . 52.0 t0 46.99 80.18 0.05 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-O 119.288 -0.387 . . . . 0.0 110.008 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 47' ' ' GLU . . . . . 0.441 ' CB ' ' CD ' ' D' ' 48' ' ' PRO . 1.3 mt-10 159.24 -68.83 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.125 0 CA-C-N 117.839 0.29 . . . . 0.0 110.382 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 48' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' D' ' 47' ' ' GLU . 37.0 Cg_endo -61.48 163.91 16.76 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 C-N-CA 121.64 1.56 . . . . 0.0 112.062 -179.533 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 49' ' ' LYS . . . . . . . . . . . . . 87.9 tttt . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.352 -179.979 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 1' ' ' FME . . . . . 0.535 ' C ' ' SD ' ' E' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 2' ' ' GLY . . . . . . . . . . . . . . . 97.51 -22.18 42.15 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -67.56 -45.19 79.38 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 4' ' ' ILE . . . . . 0.413 HD11 HG22 ' E' ' 4' ' ' ILE . 97.8 mt -113.87 108.43 25.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 5' ' ' SER . . . . . . . . . . . . . 43.9 t -119.62 123.45 43.92 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.447 0.641 . . . . 0.0 111.719 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 6' ' ' ILE . . . . . . . . . . . . . 4.9 tt -68.2 -28.31 40.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 7' ' ' TRP . . . . . . . . . . . . . 39.4 m95 -60.25 -28.87 68.39 Favored 'General case' 0 N--CA 1.463 0.221 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.553 -178.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 8' ' ' GLN . . . . . . . . . . . . . 71.6 mt-30 -59.97 -34.67 73.59 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.089 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 9' ' ' LEU . . . . . . . . . . . . . 5.8 tt -69.65 -38.7 77.24 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.545 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 10' ' ' LEU . . . . . . . . . . . . . 1.8 mt -60.98 -47.39 86.65 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 122.062 -0.399 . . . . 0.0 110.478 -179.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 11' ' ' ILE . . . . . . . . . . . . . 9.9 tt -65.24 -43.08 95.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.115 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 12' ' ' ILE . . . . . . . . . . . . . 37.5 mt -63.73 -44.12 98.23 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.16 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.781 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.05 -40.07 92.25 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.032 -179.491 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 14' ' ' VAL . . . . . . . . . . . . . 39.6 t -59.94 -45.4 95.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 15' ' ' ILE . . . . . 0.536 ' O ' ' HG ' ' E' ' 19' ' ' LEU . 71.9 mt -60.81 -44.73 98.16 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 C-N-CA 120.658 -0.417 . . . . 0.0 110.301 179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 16' ' ' VAL . . . . . . . . . . . . . 55.5 t -58.76 -45.56 91.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.802 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 17' ' ' VAL . . . . . 0.572 ' O ' ' N ' ' E' ' 21' ' ' GLY . 95.1 t -63.43 -42.88 97.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.794 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 18' ' ' LEU . . . . . . . . . . . . . 8.1 mt -65.3 -46.14 81.56 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 120.0 -0.68 . . . . 0.0 111.075 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 19' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' E' ' 15' ' ' ILE . 38.2 mt -64.06 -42.06 97.14 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.369 -179.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -89.02 -11.0 45.41 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 179.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 21' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' E' ' 17' ' ' VAL . . . 73.86 176.61 34.21 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -178.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 22' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.08 -38.74 7.6 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 117.633 0.717 . . . . 0.0 111.068 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 23' ' ' LYS . . . . . . . . . . . . . 18.8 tptm -64.09 -46.44 84.24 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.794 179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 24' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -64.23 -42.09 96.71 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.185 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 25' ' ' LEU . . . . . . . . . . . . . 7.3 tt -60.56 -22.71 63.96 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.566 -0.453 . . . . 0.0 110.69 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 26' ' ' GLY . . . . . . . . . . . . . . . -68.1 -51.16 35.21 Favored Glycine 0 C--N 1.337 0.589 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 27' ' ' SER . . . . . . . . . . . . . 79.4 p -63.31 -41.63 98.95 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 110.371 -0.233 . . . . 0.0 110.371 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 28' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.86 -46.97 94.99 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 C-N-CA 120.388 -0.525 . . . . 0.0 110.722 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.406 ' O ' ' N ' ' E' ' 33' ' ' GLY . . . -64.16 -51.25 54.52 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 120.472 -0.87 . . . . 0.0 111.069 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 30' ' ' SER . . . . . . . . . . . . . 77.7 p -60.6 -38.14 83.69 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 117.17 0.485 . . . . 0.0 110.456 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 31' ' ' ASP . . . . . . . . . . . . . 97.5 m-20 -63.81 -43.55 95.93 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.136 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 32' ' ' LEU . . . . . . . . . . . . . 68.3 mt -84.43 -11.98 55.22 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.503 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' E' ' 29' ' ' GLY . . . -85.07 6.45 79.21 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.43 -37.32 87.11 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 120.564 -0.454 . . . . 0.0 110.805 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 35' ' ' SER . . . . . . . . . . . . . 15.4 m -65.83 -36.61 83.95 Favored 'General case' 0 C--O 1.222 -0.373 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.733 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 36' ' ' ILE . . . . . . . . . . . . . 89.2 mt -61.49 -40.94 88.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.994 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 37' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -55.6 -37.82 68.6 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.531 -0.467 . . . . 0.0 109.939 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.58 -41.91 82.56 Favored Glycine 0 CA--C 1.524 0.602 0 C-N-CA 120.623 -0.798 . . . . 0.0 111.675 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 39' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -60.8 -46.74 89.35 Favored 'General case' 0 N--CA 1.456 -0.145 0 C-N-CA 119.903 -0.719 . . . . 0.0 109.603 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 40' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -58.73 -45.95 88.49 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.893 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 41' ' ' LYS . . . . . . . . . . . . . 75.2 tttt -61.82 -51.03 69.93 Favored 'General case' 0 C--O 1.227 -0.115 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.393 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.59 -43.86 84.93 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 120.094 -0.642 . . . . 0.0 111.426 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 43' ' ' MET . . . . . . . . . . . . . 18.3 ptp -77.47 14.26 1.03 Allowed 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.428 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 44' ' ' SER . . . . . . . . . . . . . 26.2 t -128.9 -11.26 4.83 Favored 'General case' 0 N--CA 1.469 0.477 0 O-C-N 121.689 -0.632 . . . . 0.0 110.817 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 45' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -66.94 -45.24 78.43 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.381 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 46' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -83.23 43.81 0.9 Allowed 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.348 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 47' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -171.29 88.16 0.47 Allowed Pre-proline 0 N--CA 1.47 0.532 0 C-N-CA 121.053 -0.259 . . . . 0.0 110.757 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 48' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -75.81 158.34 39.03 Favored 'Trans proline' 0 N--CA 1.494 1.501 0 C-N-CA 122.026 1.818 . . . . 0.0 112.309 -179.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 49' ' ' LYS . . . . . . . . . . . . . 64.7 mttp . . . . . 0 C--N 1.33 -0.245 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.809 179.795 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 1' ' ' FME . . . . . 0.586 ' SD ' ' N ' ' F' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.55 47.22 0.46 Allowed Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.94 -26.49 0.91 Allowed Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 4' ' ' ILE . . . . . . . . . . . . . 96.6 mt -94.45 103.66 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 5' ' ' SER . . . . . . . . . . . . . 13.2 t -119.54 124.92 47.58 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.606 0.717 . . . . 0.0 111.899 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 6' ' ' ILE . . . . . . . . . . . . . 10.1 tt -67.03 -33.12 61.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.669 177.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 7' ' ' TRP . . . . . . . . . . . . . 50.6 m95 -60.44 -28.88 68.63 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 114.55 -1.204 . . . . 0.0 110.29 -178.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 8' ' ' GLN . . . . . . . . . . . . . 65.4 mm-40 -59.97 -34.88 73.88 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.218 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 9' ' ' LEU . . . . . . . . . . . . . 85.8 mt -69.42 -38.7 78.01 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.561 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 10' ' ' LEU . . . . . . . . . . . . . 2.2 mt -60.87 -47.43 86.4 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 120.519 -0.473 . . . . 0.0 110.464 -178.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 11' ' ' ILE . . . . . . . . . . . . . 10.1 tt -64.78 -43.64 96.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.162 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 12' ' ' ILE . . . . . . . . . . . . . 80.2 mt -63.72 -44.21 98.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 C-N-CA 120.565 -0.454 . . . . 0.0 110.708 179.101 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.62 -40.22 91.12 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.123 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 14' ' ' VAL . . . . . . . . . . . . . 41.8 t -60.07 -45.03 96.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 15' ' ' ILE . . . . . 0.51 ' O ' ' HG ' ' F' ' 19' ' ' LEU . 69.3 mt -60.96 -44.81 98.86 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.581 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.221 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 16' ' ' VAL . . . . . . . . . . . . . 53.6 t -58.59 -45.55 90.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 C-N-CA 120.549 -0.461 . . . . 0.0 111.057 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 17' ' ' VAL . . . . . 0.573 ' O ' ' N ' ' F' ' 21' ' ' GLY . 84.2 t -63.57 -42.63 96.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.991 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 18' ' ' LEU . . . . . . . . . . . . . 4.4 mt -65.48 -45.96 81.64 Favored 'General case' 0 N--CA 1.463 0.212 0 C-N-CA 119.958 -0.697 . . . . 0.0 111.063 -179.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 19' ' ' LEU . . . . . 0.51 ' HG ' ' O ' ' F' ' 15' ' ' ILE . 39.1 mt -64.03 -42.04 97.22 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 120.322 -0.551 . . . . 0.0 110.593 -179.577 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -88.86 -10.74 46.9 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 120.73 0.3 . . . . 0.0 110.439 179.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 21' ' ' GLY . . . . . 0.573 ' N ' ' O ' ' F' ' 17' ' ' VAL . . . 73.44 176.87 33.28 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -178.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 22' ' ' THR . . . . . . . . . . . . . 81.8 m -102.53 -38.58 7.48 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 117.604 0.702 . . . . 0.0 111.1 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 23' ' ' LYS . . . . . . . . . . . . . 87.8 mttt -63.87 -46.28 85.65 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.13 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 24' ' ' LYS . . . . . . . . . . . . . 67.2 tttt -64.53 -42.15 95.92 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 110.062 -0.348 . . . . 0.0 110.062 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 25' ' ' LEU . . . . . . . . . . . . . 6.8 tt -60.44 -22.72 63.75 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.99 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 26' ' ' GLY . . . . . . . . . . . . . . . -68.06 -51.61 32.76 Favored Glycine 0 C--N 1.334 0.464 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 27' ' ' SER . . . . . . . . . . . . . 66.7 m -63.0 -41.48 99.59 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.668 179.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 28' ' ' ILE . . . . . 0.421 HD13 HG21 ' F' ' 28' ' ' ILE . 90.3 mt -63.06 -47.02 94.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.456 -179.615 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' F' ' 33' ' ' GLY . . . -64.27 -50.79 57.79 Favored Glycine 0 CA--C 1.528 0.87 0 C-N-CA 120.235 -0.983 . . . . 0.0 111.282 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 30' ' ' SER . . . . . . . . . . . . . 16.2 m -60.61 -38.27 84.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 117.239 0.519 . . . . 0.0 110.376 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 31' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -63.98 -43.74 94.83 Favored 'General case' 0 C--N 1.333 -0.148 0 C-N-CA 120.661 -0.415 . . . . 0.0 110.011 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 32' ' ' LEU . . . . . . . . . . . . . 75.4 mt -84.18 -12.15 55.38 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.339 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' F' ' 29' ' ' GLY . . . -84.89 6.02 80.25 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.47 -37.28 87.0 Favored 'General case' 0 C--N 1.332 -0.156 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.685 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 35' ' ' SER . . . . . . . . . . . . . 37.8 t -65.77 -36.53 83.8 Favored 'General case' 0 C--O 1.222 -0.38 0 CA-C-O 120.788 0.328 . . . . 0.0 110.794 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 36' ' ' ILE . . . . . . . . . . . . . 85.1 mt -61.42 -41.18 88.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 37' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -55.78 -37.51 68.66 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.52 -0.472 . . . . 0.0 109.91 -179.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.83 -41.92 80.93 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.593 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 39' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -60.55 -47.09 87.7 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.053 -0.659 . . . . 0.0 109.651 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 40' ' ' LYS . . . . . . . . . . . . . 55.8 tttp -58.45 -46.17 87.11 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.904 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 41' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -61.98 -50.85 70.44 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.365 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.57 -44.01 84.96 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 120.082 -0.647 . . . . 0.0 111.416 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 43' ' ' MET . . . . . . . . . . . . . 20.3 mtm -77.14 14.35 0.92 Allowed 'General case' 0 C--N 1.333 -0.15 0 O-C-N 122.073 -0.392 . . . . 0.0 110.592 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 44' ' ' SER . . . . . . . . . . . . . 28.8 t -169.27 80.92 0.12 Allowed 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.727 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 45' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -61.81 -45.7 92.69 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.217 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 46' ' ' ASP . . . . . 0.529 ' CG ' ' H ' ' F' ' 47' ' ' GLU . 37.7 t70 -93.93 179.05 5.47 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 121.017 -0.273 . . . . 0.0 110.289 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 47' ' ' GLU . . . . . 0.529 ' H ' ' CG ' ' F' ' 46' ' ' ASP . 16.9 tp10 -173.18 125.16 0.45 Allowed Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 48' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.02 -19.54 26.45 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 121.824 1.683 . . . . 0.0 111.903 -179.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 49' ' ' LYS . . . . . . . . . . . . . 17.4 ptpt . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.748 -179.685 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 1' ' ' FME . . . . . 0.533 ' N ' ' SD ' ' G' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.91 166.16 30.45 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . 161.64 -78.96 0.16 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 4' ' ' ILE . . . . . 0.423 HG21 HD12 ' G' ' 4' ' ' ILE . 89.7 mt -99.57 112.92 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.681 0.277 . . . . 0.0 110.389 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 5' ' ' SER . . . . . 0.502 ' OG ' ' OE1' ' G' ' 8' ' ' GLN . 35.2 t -119.61 126.26 50.74 Favored 'General case' 0 C--O 1.223 -0.324 0 CA-C-O 121.581 0.705 . . . . 0.0 111.208 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 6' ' ' ILE . . . . . . . . . . . . . 12.1 tt -66.49 -34.22 68.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.113 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 7' ' ' TRP . . . . . . . . . . . . . 45.8 m95 -58.98 -29.12 66.97 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.612 -179.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 8' ' ' GLN . . . . . 0.56 ' N ' ' OE1' ' G' ' 8' ' ' GLN . 0.9 OUTLIER -59.52 -35.03 73.4 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.336 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' G' G ' 9' ' ' LEU . . . . . . . . . . . . . 96.1 mt -69.34 -38.75 78.3 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.609 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 10' ' ' LEU . . . . . . . . . . . . . 2.5 mt -60.59 -47.56 85.66 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 122.053 -0.404 . . . . 0.0 110.833 -179.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 11' ' ' ILE . . . . . . . . . . . . . 10.9 tt -65.1 -43.31 95.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.145 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 12' ' ' ILE . . . . . . . . . . . . . 40.4 mt -63.5 -44.34 98.72 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.076 0 C-N-CA 120.944 -0.303 . . . . 0.0 110.808 178.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.0 -39.76 90.95 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.294 -179.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 14' ' ' VAL . . . . . . . . . . . . . 25.1 t -60.14 -44.83 96.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 15' ' ' ILE . . . . . 0.49 ' O ' ' HG ' ' G' ' 19' ' ' LEU . 69.8 mt -61.41 -44.66 98.91 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.897 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.236 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 16' ' ' VAL . . . . . . . . . . . . . 60.1 t -58.53 -45.77 90.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.758 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 17' ' ' VAL . . . . . 0.581 ' O ' ' N ' ' G' ' 21' ' ' GLY . 92.0 t -63.18 -43.14 98.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.93 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 18' ' ' LEU . . . . . . . . . . . . . 93.9 mt -65.04 -46.21 82.23 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.039 -179.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 19' ' ' LEU . . . . . 0.49 ' HG ' ' O ' ' G' ' 15' ' ' ILE . 52.5 mt -63.9 -42.43 97.43 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 120.724 -0.391 . . . . 0.0 110.345 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -88.55 -11.07 46.71 Favored 'General case' 0 N--CA 1.47 0.556 0 O-C-N 122.33 -0.231 . . . . 0.0 110.464 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 21' ' ' GLY . . . . . 0.581 ' N ' ' O ' ' G' ' 17' ' ' VAL . . . 73.85 176.75 34.44 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -178.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 22' ' ' THR . . . . . . . . . . . . . 18.9 m -102.36 -38.78 7.46 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 117.654 0.727 . . . . 0.0 110.945 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 23' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -63.81 -46.53 84.72 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 120.431 -0.508 . . . . 0.0 110.947 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 24' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -64.49 -41.86 96.2 Favored 'General case' 0 C--N 1.336 -0.015 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.09 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 25' ' ' LEU . . . . . . . . . . . . . 7.0 tt -60.71 -22.6 64.13 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 120.529 -0.468 . . . . 0.0 110.888 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 26' ' ' GLY . . . . . . . . . . . . . . . -68.13 -51.32 34.06 Favored Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.596 -1.002 . . . . 0.0 110.596 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 27' ' ' SER . . . . . . . . . . . . . 78.2 p -63.03 -41.35 99.51 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 121.015 -0.274 . . . . 0.0 110.827 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 28' ' ' ILE . . . . . 0.42 HG21 HD12 ' G' ' 28' ' ' ILE . 97.0 mt -63.37 -46.72 94.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.695 -179.59 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.4 ' O ' ' N ' ' G' ' 33' ' ' GLY . . . -64.2 -50.83 57.69 Favored Glycine 0 CA--C 1.529 0.931 0 C-N-CA 120.424 -0.894 . . . . 0.0 111.189 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 30' ' ' SER . . . . . . . . . . . . . 22.5 m -60.83 -38.43 85.44 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 117.255 0.528 . . . . 0.0 110.353 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 31' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -63.6 -43.73 96.07 Favored 'General case' 0 C--N 1.332 -0.17 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.121 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 32' ' ' LEU . . . . . . . . . . . . . 74.7 mt -84.52 -11.57 55.84 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.296 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' G' ' 29' ' ' GLY . . . -85.34 6.4 79.96 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.111 -0.795 . . . . 0.0 111.111 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 34' ' ' ALA . . . . . 0.462 ' O ' ' HG3' ' G' ' 37' ' ' LYS . . . -64.35 -37.49 87.68 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 117.148 0.474 . . . . 0.0 110.841 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -65.86 -36.28 83.01 Favored 'General case' 0 C--O 1.226 -0.141 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.79 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 36' ' ' ILE . . . . . . . . . . . . . 82.0 mt -61.77 -40.64 87.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 37' ' ' LYS . . . . . 0.462 ' HG3' ' O ' ' G' ' 34' ' ' ALA . 0.0 OUTLIER -55.94 -37.48 69.04 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.879 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . 0.453 ' N ' ' HG3' ' G' ' 37' ' ' LYS . . . -68.89 -41.98 80.27 Favored Glycine 0 CA--C 1.524 0.597 0 C-N-CA 120.579 -0.82 . . . . 0.0 111.647 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 39' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -60.56 -46.79 88.88 Favored 'General case' 0 C--N 1.334 -0.088 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.69 179.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 40' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -58.73 -45.84 88.73 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.121 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 41' ' ' LYS . . . . . 0.468 ' O ' ' OG ' ' G' ' 44' ' ' SER . 47.1 mmtt -61.83 -51.13 69.48 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.266 -179.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.73 -43.78 85.53 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.381 -179.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 43' ' ' MET . . . . . 0.425 ' O ' ' OD1' ' G' ' 46' ' ' ASP . 3.4 mtm -77.32 15.21 0.79 Allowed 'General case' 0 N--CA 1.456 -0.167 0 O-C-N 122.075 -0.391 . . . . 0.0 110.405 179.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 44' ' ' SER . . . . . 0.468 ' OG ' ' O ' ' G' ' 41' ' ' LYS . 84.0 p -71.78 -10.93 60.5 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 111.596 0.221 . . . . 0.0 111.596 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 45' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -61.54 -45.02 95.95 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.841 -0.344 . . . . 0.0 111.11 -179.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 46' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' G' ' 43' ' ' MET . 41.4 p30 -90.02 45.94 1.31 Allowed 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 121.216 -0.193 . . . . 0.0 110.772 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 47' ' ' GLU . . . . . . . . . . . . . 73.5 mt-10 -151.71 94.48 3.37 Favored Pre-proline 0 CA--C 1.536 0.406 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 48' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -53.34 140.81 62.19 Favored 'Trans proline' 0 N--CA 1.498 1.764 0 C-N-CA 122.204 1.936 . . . . 0.0 112.216 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 49' ' ' LYS . . . . . . . . . . . . . 27.5 mmtp . . . . . 0 C--N 1.327 -0.385 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.344 -178.931 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.15 161.72 29.4 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 111.061 -0.815 . . . . 0.0 111.061 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -163.29 149.75 17.69 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 4' ' ' ILE . . . . . . . . . . . . . 50.6 mt 38.99 67.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 120.802 0.334 . . . . 0.0 110.317 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 5' ' ' SER . . . . . . . . . . . . . 18.3 t -117.2 129.67 56.09 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.301 0.572 . . . . 0.0 111.736 -178.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 6' ' ' ILE . . . . . . . . . . . . . 14.3 tt -65.68 -32.32 57.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.481 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 7' ' ' TRP . . . . . . . . . . . . . 46.1 m95 -56.92 -28.62 62.24 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.128 -1.397 . . . . 0.0 110.431 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 8' ' ' GLN . . . . . . . . . . . . . 52.9 mt-30 -60.04 -34.72 73.77 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.389 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 9' ' ' LEU . . . . . . . . . . . . . 36.2 mt -69.76 -38.49 76.78 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.534 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 10' ' ' LEU . . . . . . . . . . . . . 2.9 mt -60.76 -47.66 85.31 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.376 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 11' ' ' ILE . . . . . . . . . . . . . 10.5 tt -64.92 -43.39 96.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.111 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 12' ' ' ILE . . . . . . . . . . . . . 40.7 mt -63.83 -43.87 97.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.791 179.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.83 -40.32 92.34 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.077 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 14' ' ' VAL . . . . . . . . . . . . . 24.8 t -59.77 -45.42 94.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 15' ' ' ILE . . . . . 0.523 ' O ' ' HG ' ' H' ' 19' ' ' LEU . 74.2 mt -61.12 -44.61 98.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.64 0 C-N-CA 120.375 -0.53 . . . . 0.0 110.167 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 16' ' ' VAL . . . . . . . . . . . . . 41.8 t -58.69 -45.42 90.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 O-C-N 121.957 -0.464 . . . . 0.0 110.987 179.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 17' ' ' VAL . . . . . 0.576 ' O ' ' N ' ' H' ' 21' ' ' GLY . 84.0 t -63.53 -42.82 97.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.942 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 18' ' ' LEU . . . . . . . . . . . . . 4.8 mt -65.56 -45.83 81.83 Favored 'General case' 0 N--CA 1.465 0.285 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.009 -179.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 19' ' ' LEU . . . . . 0.523 ' HG ' ' O ' ' H' ' 15' ' ' ILE . 28.9 mt -64.04 -42.16 97.15 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.518 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -89.05 -10.81 46.08 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 21' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' H' ' 17' ' ' VAL . . . 73.72 176.66 33.82 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.303 -1.519 . . . . 0.0 109.303 -178.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 22' ' ' THR . . . . . . . . . . . . . 29.6 m -102.05 -38.67 7.64 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 117.408 0.604 . . . . 0.0 111.289 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 23' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -63.89 -46.49 84.64 Favored 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 120.523 -0.471 . . . . 0.0 110.781 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 24' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -64.31 -42.06 96.52 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.027 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 25' ' ' LEU . . . . . . . . . . . . . 8.0 tt -60.83 -22.75 64.51 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.874 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.93 -51.32 35.24 Favored Glycine 0 C--N 1.334 0.436 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 27' ' ' SER . . . . . . . . . . . . . 78.2 p -63.12 -41.29 99.32 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.819 179.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 28' ' ' ILE . . . . . 0.405 HD13 HG23 ' H' ' 28' ' ' ILE . 97.0 mt -63.28 -46.89 94.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 C-N-CA 120.498 -0.481 . . . . 0.0 110.699 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' H' ' 33' ' ' GLY . . . -64.32 -50.54 59.18 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 120.16 -1.019 . . . . 0.0 111.437 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 30' ' ' SER . . . . . . . . . . . . . 15.8 m -61.07 -37.98 84.59 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 117.322 0.561 . . . . 0.0 110.455 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 31' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -64.01 -43.62 95.06 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.262 179.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -84.28 -11.86 55.69 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.391 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' H' ' 29' ' ' GLY . . . -85.24 6.59 79.09 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.41 -37.35 87.21 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.744 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -65.85 -36.68 84.13 Favored 'General case' 0 C--O 1.222 -0.357 0 C-N-CA 120.985 -0.286 . . . . 0.0 110.491 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 36' ' ' ILE . . . . . . . . . . . . . 90.2 mt -61.4 -41.01 88.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 37' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -55.49 -37.82 68.33 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.911 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.9 -41.69 81.37 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 120.251 -0.975 . . . . 0.0 111.592 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 39' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -60.99 -46.62 90.02 Favored 'General case' 0 C--N 1.333 -0.126 0 C-N-CA 119.912 -0.715 . . . . 0.0 109.518 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 40' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -58.71 -46.09 88.1 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.034 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 41' ' ' LYS . . . . . . . . . . . . . 27.5 tptp -61.86 -50.89 70.44 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.298 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.71 -43.8 85.48 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 120.017 -0.673 . . . . 0.0 111.377 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 43' ' ' MET . . . . . . . . . . . . . 19.7 mtm -77.26 14.46 0.93 Allowed 'General case' 0 N--CA 1.463 0.212 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.275 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 44' ' ' SER . . . . . . . . . . . . . 22.6 t -138.9 44.32 2.05 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 120.727 0.299 . . . . 0.0 110.851 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 45' ' ' ASP . . . . . 0.608 ' C ' ' H ' ' H' ' 47' ' ' GLU . 40.7 t0 -62.72 -43.09 99.71 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.673 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 46' ' ' ASP . . . . . . . . . . . . . 41.2 t0 62.95 -25.94 0.06 Allowed 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 47' ' ' GLU . . . . . 0.608 ' H ' ' C ' ' H' ' 45' ' ' ASP . 7.1 pt-20 -175.62 158.76 1.98 Allowed Pre-proline 0 CA--C 1.537 0.474 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 48' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.23 -39.27 81.29 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 121.689 1.593 . . . . 0.0 112.185 178.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 49' ' ' LYS . . . . . . . . . . . . . 66.1 tttm . . . . . 0 C--N 1.331 -0.21 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.612 -179.98 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.7 -121.64 0.86 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 3' ' ' GLY . . . . . . . . . . . . . . . 92.14 -6.89 78.83 Favored Glycine 0 N--CA 1.467 0.714 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 4' ' ' ILE . . . . . 0.531 ' H ' ' CD1' ' I' ' 4' ' ' ILE . 0.1 OUTLIER -130.83 166.59 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 -179.569 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' I' I ' 5' ' ' SER . . . . . 0.585 ' OG ' ' NE2' ' I' ' 8' ' ' GLN . 0.3 OUTLIER -138.81 82.29 1.89 Allowed 'General case' 0 CA--C 1.533 0.311 0 CA-C-O 121.473 0.654 . . . . 0.0 110.639 179.536 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' I' I ' 6' ' ' ILE . . . . . . . . . . . . . 34.2 mm -71.36 -43.45 73.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.395 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 7' ' ' TRP . . . . . . . . . . . . . 20.5 m95 -54.92 -29.04 55.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.725 -178.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 8' ' ' GLN . . . . . 0.67 ' NE2' ' N ' ' I' ' 8' ' ' GLN . 0.4 OUTLIER -59.95 -34.74 73.67 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.379 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' I' I ' 9' ' ' LEU . . . . . . . . . . . . . 92.3 mt -69.62 -38.59 77.3 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.588 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 10' ' ' LEU . . . . . 0.45 ' N ' ' CD1' ' I' ' 10' ' ' LEU . 9.6 mp -60.82 -47.33 86.82 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.77 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 11' ' ' ILE . . . . . 0.449 HG21 ' O ' ' I' ' 8' ' ' GLN . 9.5 tt -64.95 -43.65 96.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 C-N-CA 120.749 -0.38 . . . . 0.0 109.984 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 12' ' ' ILE . . . . . 0.405 ' N ' ' CG2' ' I' ' 11' ' ' ILE . 1.4 mm -63.59 -43.94 98.4 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.727 179.171 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.13 -40.03 92.27 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.208 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 14' ' ' VAL . . . . . . . . . . . . . 22.6 t -60.01 -44.97 95.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 15' ' ' ILE . . . . . 0.482 ' O ' ' HG ' ' I' ' 19' ' ' LEU . 7.0 mm -61.01 -44.8 98.98 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.702 0 C-N-CA 120.653 -0.419 . . . . 0.0 110.188 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 16' ' ' VAL . . . . . . . . . . . . . 49.5 t -58.69 -45.49 90.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 C-N-CA 120.456 -0.498 . . . . 0.0 111.09 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 17' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' I' ' 21' ' ' GLY . 91.9 t -63.36 -42.87 97.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.947 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 18' ' ' LEU . . . . . . . . . . . . . 10.3 mt -65.34 -46.09 81.64 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 119.974 -0.69 . . . . 0.0 110.94 -179.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 19' ' ' LEU . . . . . 0.482 ' HG ' ' O ' ' I' ' 15' ' ' ILE . 48.3 mt -63.95 -42.43 97.3 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 120.839 -0.344 . . . . 0.0 110.278 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 32.6 m-85 -88.82 -10.71 47.1 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.7 0.286 . . . . 0.0 110.583 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 21' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' I' ' 17' ' ' VAL . . . 73.82 176.51 33.9 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.052 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 22' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.19 -38.77 7.54 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 117.536 0.668 . . . . 0.0 110.908 -179.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 23' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -64.09 -46.71 83.06 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.531 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 24' ' ' LYS . . . . . . . . . . . . . 16.9 tptp -64.35 -42.08 96.42 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 110.005 -0.369 . . . . 0.0 110.005 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 25' ' ' LEU . . . . . . . . . . . . . 6.5 tt -60.73 -22.48 64.04 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.801 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 26' ' ' GLY . . . . . . . . . . . . . . . -68.05 -51.42 33.99 Favored Glycine 0 C--N 1.334 0.465 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 27' ' ' SER . . . . . . . . . . . . . 42.9 m -62.89 -41.76 99.53 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.666 179.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 28' ' ' ILE . . . . . 0.408 HD11 HG22 ' I' ' 28' ' ' ILE . 91.5 mt -63.07 -46.92 94.89 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 C-N-CA 120.586 -0.445 . . . . 0.0 110.546 -179.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' I' ' 33' ' ' GLY . . . -64.03 -51.26 54.73 Favored Glycine 0 CA--C 1.53 1.001 0 C-N-CA 120.549 -0.834 . . . . 0.0 111.193 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 30' ' ' SER . . . . . . . . . . . . . 77.4 p -60.46 -38.42 84.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 117.068 0.434 . . . . 0.0 110.298 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 31' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -63.91 -43.53 95.66 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.185 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 32' ' ' LEU . . . . . . . . . . . . . 71.2 mt -84.32 -11.86 55.62 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.489 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' I' ' 29' ' ' GLY . . . -85.21 6.68 78.7 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.39 -37.63 88.19 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 117.006 0.403 . . . . 0.0 110.712 -179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -65.67 -36.53 83.93 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.901 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 36' ' ' ILE . . . . . 0.401 HG22 HD13 ' I' ' 36' ' ' ILE . 86.6 mt -61.56 -40.98 88.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.76 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 37' ' ' LYS . . . . . . . . . . . . . 55.0 mtpt -55.64 -37.65 68.5 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.384 -0.526 . . . . 0.0 110.074 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.59 -42.09 81.94 Favored Glycine 0 C--N 1.334 0.434 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.634 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 39' ' ' PHE . . . . . 0.427 ' CD1' ' C ' ' I' ' 39' ' ' PHE . 18.7 t80 -60.62 -46.93 88.42 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.146 -0.622 . . . . 0.0 109.554 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 40' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -58.72 -46.0 88.32 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.889 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 41' ' ' LYS . . . . . . . . . . . . . 66.2 tttm -61.8 -51.04 69.92 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.24 -179.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 42' ' ' ALA . . . . . 0.438 ' C ' ' H ' ' I' ' 44' ' ' SER . . . -57.65 -43.84 85.2 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.404 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 43' ' ' MET . . . . . . . . . . . . . 16.3 ttp -77.14 17.68 0.44 Allowed 'General case' 0 C--O 1.233 0.211 0 C-N-CA 120.829 -0.348 . . . . 0.0 110.442 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 44' ' ' SER . . . . . 0.438 ' H ' ' C ' ' I' ' 42' ' ' ALA . 17.9 m -136.6 -4.89 2.01 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 178.378 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 45' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -64.61 -46.68 81.6 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.064 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 46' ' ' ASP . . . . . 0.536 ' OD1' ' N ' ' I' ' 47' ' ' GLU . 1.2 p30 -40.41 -51.94 2.79 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 120.896 -0.322 . . . . 0.0 111.142 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 47' ' ' GLU . . . . . 0.536 ' N ' ' OD1' ' I' ' 46' ' ' ASP . 2.1 tm-20 -178.41 117.69 0.24 Allowed Pre-proline 0 CA--C 1.546 0.82 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.376 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 48' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -74.69 -14.38 21.93 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 121.672 1.581 . . . . 0.0 112.022 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 49' ' ' LYS . . . . . . . . . . . . . 99.1 mttt . . . . . 0 N--CA 1.465 0.288 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.502 -179.566 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' FME . . . . . 0.497 ' SD ' ' N ' ' A' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.16 175.51 44.13 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 82.83 14.07 76.3 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.3 tt -136.21 149.66 27.52 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.78 0.324 . . . . 0.0 110.474 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.411 ' O ' ' OE1' ' A' ' 8' ' ' GLN . 0.4 OUTLIER 49.37 18.85 0.29 Allowed 'General case' 0 C--O 1.222 -0.346 0 CA-C-O 120.946 0.403 . . . . 0.0 110.276 -179.59 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.6 pt -49.49 -32.15 6.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-O 121.164 0.507 . . . . 0.0 109.796 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.537 ' CH2' ' O ' ' I' ' 5' ' ' SER . 35.5 m95 -60.44 -28.91 68.66 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.443 -179.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.411 ' OE1' ' O ' ' A' ' 5' ' ' SER . 9.7 mp0 -60.03 -34.52 73.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.025 0.44 . . . . 0.0 110.328 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.8 tt -69.9 -38.57 76.36 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.454 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.513 ' O ' HG23 ' A' ' 14' ' ' VAL . 6.1 mp -60.69 -47.44 86.26 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.773 -179.351 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.4 tt -64.89 -43.59 96.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.171 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 34.1 mt -63.68 -44.21 98.35 Favored 'Isoleucine or valine' 0 C--N 1.343 0.296 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.667 179.112 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.82 -39.96 90.98 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.239 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.598 HG11 ' CG2' ' I' ' 12' ' ' ILE . 41.8 t -60.22 -44.82 96.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 C-N-CA 120.69 -0.404 . . . . 0.0 109.967 179.753 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.8 mt -61.28 -44.52 98.58 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.574 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.198 179.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.1 t -58.86 -45.4 91.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.498 -0.481 . . . . 0.0 110.853 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.573 ' O ' ' N ' ' A' ' 21' ' ' GLY . 77.1 t -63.36 -43.08 98.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.876 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 46.5 mt -65.08 -46.64 80.3 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 121.722 -0.611 . . . . 0.0 110.854 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 77.6 mt -63.65 -42.22 98.12 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.546 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -89.16 -10.74 46.06 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.312 179.235 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.573 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 73.82 176.72 34.31 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.091 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.445 HG23 ' N ' ' A' ' 23' ' ' LYS . 9.5 t -102.02 -39.17 7.44 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 117.752 0.776 . . . . 0.0 111.043 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.445 ' N ' HG23 ' A' ' 22' ' ' THR . 38.7 ttmt -63.84 -46.47 84.9 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.835 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -64.46 -41.93 96.23 Favored 'General case' 0 C--O 1.227 -0.119 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.081 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 6.8 tt -60.61 -22.81 64.17 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.939 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.73 -51.73 33.79 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 77.9 p -62.89 -41.48 99.43 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.753 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 96.7 mt -62.78 -47.43 92.91 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.746 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.406 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -64.07 -50.97 57.02 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.238 -0.982 . . . . 0.0 111.437 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.4 m -60.66 -38.21 84.12 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 117.207 0.503 . . . . 0.0 110.403 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -63.75 -43.46 96.38 Favored 'General case' 0 C--N 1.33 -0.26 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.297 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 66.9 mt -84.59 -12.05 54.82 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.261 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -85.19 6.98 77.58 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 120.657 -0.783 . . . . 0.0 111.268 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.72 -37.33 87.24 Favored 'General case' 0 C--N 1.331 -0.21 0 O-C-N 122.444 -0.445 . . . . 0.0 110.778 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 68.7 p -65.7 -36.68 84.33 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-O 120.907 0.384 . . . . 0.0 110.782 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 90.4 mt -61.36 -40.88 87.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.072 179.655 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -55.84 -37.6 68.94 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 120.511 -0.476 . . . . 0.0 109.836 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.72 -41.87 81.82 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.764 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.484 ' O ' ' SD ' ' A' ' 43' ' ' MET . 7.6 m-85 -60.83 -46.78 89.23 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 119.936 -0.706 . . . . 0.0 109.549 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -58.57 -46.14 87.53 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.071 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -61.68 -51.04 70.08 Favored 'General case' 0 N--CA 1.457 -0.124 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.407 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.59 -43.91 84.97 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.313 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.531 ' SD ' ' N ' ' A' ' 43' ' ' MET . 0.0 OUTLIER -77.24 17.09 0.5 Allowed 'General case' 0 CA--C 1.531 0.223 0 O-C-N 122.206 -0.308 . . . . 0.0 110.224 179.981 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 78.5 p -71.54 -15.53 62.29 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 120.823 0.344 . . . . 0.0 110.475 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 36.2 p-10 -60.96 -42.18 97.77 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.019 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.519 ' N ' ' OD1' ' A' ' 45' ' ' ASP . 92.4 m-20 -109.28 52.3 0.72 Allowed 'General case' 0 N--CA 1.469 0.483 0 O-C-N 122.461 -0.149 . . . . 0.0 110.806 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -175.89 96.14 0.26 Allowed Pre-proline 0 CA--C 1.535 0.388 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -76.25 150.38 32.88 Favored 'Trans proline' 0 N--CA 1.491 1.326 0 C-N-CA 121.787 1.658 . . . . 0.0 112.078 -179.395 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 98.9 mttt . . . . . 0 N--CA 1.464 0.238 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.458 -179.954 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 1' ' ' FME . . . . . 0.593 ' N ' ' SD ' ' B' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.0 98.22 0.13 Allowed Glycine 0 CA--C 1.526 0.734 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -64.66 -39.21 96.54 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 4' ' ' ILE . . . . . . . . . . . . . 80.0 mt -68.86 86.1 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 40.1 t -117.59 124.16 47.98 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 121.227 0.537 . . . . 0.0 111.313 -179.447 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 6' ' ' ILE . . . . . . . . . . . . . 16.7 tt -67.64 -32.53 57.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.373 -0.831 . . . . 0.0 109.389 178.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 7' ' ' TRP . . . . . . . . . . . . . 48.4 m95 -62.61 -28.79 70.14 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.564 -178.304 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 8' ' ' GLN . . . . . . . . . . . . . 56.7 mm-40 -60.08 -34.99 74.2 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 96.8 mt -69.41 -38.58 77.99 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.629 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.418 ' O ' HG23 ' B' ' 14' ' ' VAL . 2.2 mt -61.14 -47.55 85.73 Favored 'General case' 0 N--CA 1.468 0.455 0 O-C-N 121.788 -0.57 . . . . 0.0 110.361 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 11' ' ' ILE . . . . . . . . . . . . . 9.5 tt -65.01 -43.46 96.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.049 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 52.3 mt -63.77 -43.62 98.02 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.933 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.19 -39.98 92.21 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.74 -0.384 . . . . 0.0 110.118 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.418 HG23 ' O ' ' B' ' 10' ' ' LEU . 51.1 t -60.07 -45.01 96.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.492 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 55.3 mt -60.89 -44.75 98.48 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.615 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.321 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 16' ' ' VAL . . . . . . . . . . . . . 48.9 t -58.88 -45.44 91.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.757 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' VAL . . . . . 0.566 ' O ' ' N ' ' B' ' 21' ' ' GLY . 95.2 t -63.52 -42.9 97.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.719 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 18' ' ' LEU . . . . . . . . . . . . . 4.5 mt -65.31 -46.15 81.5 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 119.904 -0.718 . . . . 0.0 111.13 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' B' ' 15' ' ' ILE . 51.7 mt -63.89 -42.11 97.54 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.517 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -88.85 -10.89 46.38 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 110.299 -0.26 . . . . 0.0 110.299 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' B' ' 17' ' ' VAL . . . 73.63 176.57 33.34 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 -178.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 22' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.02 -38.78 7.61 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 117.291 0.545 . . . . 0.0 111.152 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -63.82 -46.5 84.82 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.323 -0.551 . . . . 0.0 110.94 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 24' ' ' LYS . . . . . . . . . . . . . 41.7 tptt -64.54 -41.88 96.07 Favored 'General case' 0 N--CA 1.455 -0.221 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.405 ' C ' HD23 ' B' ' 25' ' ' LEU . 7.3 tt -60.33 -22.89 63.75 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.09 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.89 -51.37 35.13 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 120.197 -1.001 . . . . 0.0 110.674 -179.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 27' ' ' SER . . . . . . . . . . . . . 45.2 t -62.95 -41.67 99.59 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.68 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' ILE . . . . . . . . . . . . . 95.4 mt -63.18 -46.68 95.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 120.529 -0.468 . . . . 0.0 110.794 -179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.02 -51.19 55.28 Favored Glycine 0 CA--C 1.526 0.755 0 C-N-CA 120.6 -0.81 . . . . 0.0 111.418 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 30' ' ' SER . . . . . . . . . . . . . 20.0 m -60.64 -38.4 84.68 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 117.09 0.445 . . . . 0.0 110.349 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -63.81 -43.46 96.19 Favored 'General case' 0 C--N 1.331 -0.208 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.168 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 76.7 mt -84.51 -11.83 55.38 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.213 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -85.43 6.86 78.6 Favored Glycine 0 CA--C 1.531 1.059 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.224 -179.668 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.58 -37.24 86.87 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 120.48 -0.488 . . . . 0.0 110.999 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 35' ' ' SER . . . . . . . . . . . . . 66.4 p -65.83 -36.67 84.11 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.508 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 36' ' ' ILE . . . . . . . . . . . . . 87.5 mt -61.4 -41.24 89.14 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 37' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -55.65 -37.73 68.63 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.826 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.73 -42.12 80.84 Favored Glycine 0 CA--C 1.527 0.794 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.514 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -60.11 -47.12 87.21 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 120.212 -0.595 . . . . 0.0 109.826 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 46.2 tptt -58.98 -45.9 89.44 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.857 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 41' ' ' LYS . . . . . . . . . . . . . 45.2 mmtt -61.52 -51.19 69.66 Favored 'General case' 0 C--O 1.227 -0.087 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.374 -179.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.78 -43.71 85.76 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 120.008 -0.677 . . . . 0.0 111.254 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 43' ' ' MET . . . . . . . . . . . . . 2.4 mpp? -77.27 14.0 1.03 Allowed 'General case' 0 C--N 1.331 -0.196 0 O-C-N 122.185 -0.322 . . . . 0.0 110.372 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 44' ' ' SER . . . . . . . . . . . . . 57.7 m -153.66 38.81 0.48 Allowed 'General case' 0 N--CA 1.462 0.169 0 CA-C-O 120.753 0.311 . . . . 0.0 110.75 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 45' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -61.4 -42.82 99.33 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.27 -0.423 . . . . 0.0 109.88 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -81.94 44.61 0.85 Allowed 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 121.306 0.574 . . . . 0.0 110.395 179.168 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 47' ' ' GLU . . . . . . . . . . . . . 30.2 tp10 -171.74 88.21 0.45 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.487 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 48' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_exo -62.13 147.86 94.28 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 C-N-CA 122.436 2.091 . . . . 0.0 112.059 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt . . . . . 0 N--CA 1.467 0.385 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.297 -179.853 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 2' ' ' GLY . . . . . . . . . . . . . . . 57.93 -112.18 3.64 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -66.82 -176.19 7.57 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 4' ' ' ILE . . . . . . . . . . . . . 80.5 mt 55.38 79.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 5' ' ' SER . . . . . . . . . . . . . 45.4 t -119.8 125.87 49.63 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 121.419 0.628 . . . . 0.0 112.545 -179.026 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 tt -66.3 -32.82 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.271 -0.877 . . . . 0.0 108.744 177.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 7' ' ' TRP . . . . . . . . . . . . . 44.5 m95 -57.14 -28.85 63.1 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.414 -1.267 . . . . 0.0 110.625 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 8' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -59.61 -35.07 73.61 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.854 0.359 . . . . 0.0 110.303 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 9' ' ' LEU . . . . . . . . . . . . . 80.9 mt -69.51 -38.52 77.61 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.771 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 10' ' ' LEU . . . . . . . . . . . . . 3.0 mt -61.05 -47.41 86.48 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.613 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 11' ' ' ILE . . . . . . . . . . . . . 13.2 tt -65.12 -43.22 95.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 120.441 -0.503 . . . . 0.0 110.192 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 12' ' ' ILE . . . . . . . . . . . . . 69.2 mt -63.69 -44.25 98.35 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.498 178.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.97 -40.11 92.17 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 14' ' ' VAL . . . . . . . . . . . . . 25.5 t -59.93 -45.2 95.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 C-N-CA 120.723 -0.391 . . . . 0.0 109.977 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 15' ' ' ILE . . . . . 0.527 ' O ' ' HG ' ' C' ' 19' ' ' LEU . 70.1 mt -60.8 -44.89 98.48 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.722 0 C-N-CA 120.424 -0.511 . . . . 0.0 110.238 179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 16' ' ' VAL . . . . . . . . . . . . . 25.5 t -58.74 -45.46 91.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.94 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 17' ' ' VAL . . . . . 0.583 ' O ' ' N ' ' C' ' 21' ' ' GLY . 71.1 t -63.27 -43.06 98.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 C-N-CA 120.91 -0.316 . . . . 0.0 110.933 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 18' ' ' LEU . . . . . 0.419 HD23 ' HA ' ' C' ' 18' ' ' LEU . 79.9 mt -65.22 -46.19 81.64 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.953 -179.458 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 19' ' ' LEU . . . . . 0.527 ' HG ' ' O ' ' C' ' 15' ' ' ILE . 45.1 mt -63.83 -42.36 97.66 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.288 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -88.91 -10.78 46.59 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 120.652 0.263 . . . . 0.0 110.317 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 21' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' C' ' 17' ' ' VAL . . . 73.64 176.54 33.33 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -178.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 22' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.0 -38.79 7.61 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 117.333 0.567 . . . . 0.0 111.168 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 23' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -63.88 -46.76 83.47 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.801 179.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 24' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -64.36 -41.85 96.51 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.896 0.379 . . . . 0.0 110.122 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 25' ' ' LEU . . . . . . . . . . . . . 7.3 tt -60.46 -23.05 64.14 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.93 179.557 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.89 -51.34 35.26 Favored Glycine 0 C--N 1.334 0.451 0 C-N-CA 120.208 -0.996 . . . . 0.0 110.683 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 27' ' ' SER . . . . . . . . . . . . . 77.8 p -62.86 -41.69 99.47 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 121.141 -0.223 . . . . 0.0 110.664 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 28' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.94 -47.0 94.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 C-N-CA 120.469 -0.492 . . . . 0.0 110.632 -179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.406 ' O ' ' N ' ' C' ' 33' ' ' GLY . . . -64.34 -50.87 57.15 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.173 -179.566 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 30' ' ' SER . . . . . . . . . . . . . 24.8 m -60.62 -38.51 84.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 117.332 0.566 . . . . 0.0 110.404 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 31' ' ' ASP . . . . . . . . . . . . . 75.2 m-20 -63.67 -43.65 96.08 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.114 179.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 32' ' ' LEU . . . . . . . . . . . . . 73.3 mt -84.48 -11.86 55.37 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.362 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' C' ' 29' ' ' GLY . . . -85.14 6.55 79.01 Favored Glycine 0 CA--C 1.528 0.844 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.41 -37.43 87.48 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.735 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 35' ' ' SER . . . . . . . . . . . . . 15.5 m -65.63 -36.79 84.73 Favored 'General case' 0 C--O 1.22 -0.482 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.837 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 87.1 mt -61.3 -41.09 88.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.049 179.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 37' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -55.51 -37.72 68.25 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.834 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.86 -42.03 80.27 Favored Glycine 0 CA--C 1.523 0.584 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.597 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 39' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -60.62 -46.89 88.59 Favored 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 119.93 -0.708 . . . . 0.0 109.715 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 40' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -58.68 -45.86 88.53 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.059 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 41' ' ' LYS . . . . . . . . . . . . . 40.2 tttp -61.87 -50.96 70.14 Favored 'General case' 0 C--O 1.224 -0.273 0 CA-C-N 116.532 -0.303 . . . . 0.0 111.363 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.71 -43.98 85.59 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 120.056 -0.658 . . . . 0.0 111.237 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 43' ' ' MET . . . . . . . . . . . . . 33.8 ttm -77.21 14.39 0.93 Allowed 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.472 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 44' ' ' SER . . . . . . . . . . . . . 12.7 p -134.01 -28.96 1.32 Allowed 'General case' 0 N--CA 1.47 0.543 0 O-C-N 121.755 -0.59 . . . . 0.0 110.952 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 45' ' ' ASP . . . . . 0.415 ' O ' ' OD1' ' C' ' 46' ' ' ASP . 31.0 t70 -59.32 -48.26 82.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.758 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 46' ' ' ASP . . . . . 0.415 ' OD1' ' O ' ' C' ' 45' ' ' ASP . 5.8 p-10 39.0 54.94 2.09 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.616 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 47' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -170.1 87.75 0.55 Allowed Pre-proline 0 N--CA 1.465 0.322 0 N-CA-C 110.414 -0.217 . . . . 0.0 110.414 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 48' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -76.52 157.0 36.51 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.852 1.701 . . . . 0.0 112.321 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 49' ' ' LYS . . . . . . . . . . . . . 54.0 mttp . . . . . 0 C--N 1.332 -0.164 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.43 179.994 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 2' ' ' GLY . . . . . . . . . . . . . . . -64.2 145.51 49.69 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.799 -0.921 . . . . 0.0 110.799 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -82.9 -71.48 1.31 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 4' ' ' ILE . . . . . . . . . . . . . 75.8 mt 40.5 77.72 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-O 120.835 0.35 . . . . 0.0 110.138 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 5' ' ' SER . . . . . . . . . . . . . 4.1 t -114.78 131.42 56.8 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.632 0.729 . . . . 0.0 111.571 -178.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 6' ' ' ILE . . . . . . . . . . . . . 5.2 tt -66.03 -25.35 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.308 179.282 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 7' ' ' TRP . . . . . 0.438 ' HA ' HD12 ' D' ' 10' ' ' LEU . 34.9 m95 -62.07 -28.87 69.91 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 117.023 -1.871 . . . . 0.0 110.635 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 8' ' ' GLN . . . . . 0.646 ' OE1' ' N ' ' D' ' 8' ' ' GLN . 6.8 mp0 -60.12 -34.71 73.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.069 0.462 . . . . 0.0 110.178 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 9' ' ' LEU . . . . . 0.601 ' C ' HD23 ' D' ' 9' ' ' LEU . 5.0 tt -69.65 -38.63 77.21 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.513 179.702 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 10' ' ' LEU . . . . . 0.438 HD12 ' HA ' ' D' ' 7' ' ' TRP . 3.8 mt -61.02 -47.16 87.71 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 120.446 -0.502 . . . . 0.0 110.721 -179.025 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 11' ' ' ILE . . . . . . . . . . . . . 11.0 tt -65.11 -43.32 95.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.001 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 12' ' ' ILE . . . . . . . . . . . . . 44.1 mt -63.73 -44.14 98.23 Favored 'Isoleucine or valine' 0 C--N 1.338 0.09 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.918 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.62 -40.26 91.25 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.27 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 14' ' ' VAL . . . . . 0.635 ' O ' ' HG ' ' D' ' 18' ' ' LEU . 36.0 t -60.02 -44.81 95.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.932 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 15' ' ' ILE . . . . . 0.448 ' O ' ' HG ' ' D' ' 19' ' ' LEU . 38.8 mt -61.19 -44.79 99.05 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.84 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.169 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 16' ' ' VAL . . . . . . . . . . . . . 55.9 t -58.63 -45.48 90.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 C-N-CA 120.543 -0.463 . . . . 0.0 111.004 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 17' ' ' VAL . . . . . 0.575 ' O ' ' N ' ' D' ' 21' ' ' GLY . 74.1 t -63.27 -42.91 98.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 C-N-CA 120.779 -0.369 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 18' ' ' LEU . . . . . 0.635 ' HG ' ' O ' ' D' ' 14' ' ' VAL . 6.6 mt -65.45 -45.96 81.72 Favored 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 120.046 -0.662 . . . . 0.0 110.945 -179.529 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 19' ' ' LEU . . . . . 0.503 HD12 HD13 ' E' ' 18' ' ' LEU . 56.4 mt -63.81 -42.44 97.67 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.298 -179.48 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.403 ' CE2' HD21 ' E' ' 18' ' ' LEU . 36.2 m-85 -88.99 -10.8 46.27 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 120.718 0.294 . . . . 0.0 110.258 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 21' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' D' ' 17' ' ' VAL . . . 73.47 176.62 32.87 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -178.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 22' ' ' THR . . . . . . . . . . . . . 2.6 p -102.21 -38.71 7.56 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 117.466 0.633 . . . . 0.0 111.093 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 23' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -63.67 -46.66 84.56 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.925 179.294 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 24' ' ' LYS . . . . . . . . . . . . . 64.9 mttp -64.42 -42.1 96.22 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 25' ' ' LEU . . . . . 0.414 ' C ' HD23 ' D' ' 25' ' ' LEU . 7.4 tt -60.33 -23.01 63.89 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 120.502 -0.479 . . . . 0.0 111.126 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.93 -51.31 35.28 Favored Glycine 0 C--N 1.338 0.655 0 C-N-CA 120.205 -0.998 . . . . 0.0 110.864 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 27' ' ' SER . . . . . . . . . . . . . 78.1 p -63.04 -41.19 99.45 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.758 179.314 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 28' ' ' ILE . . . . . . . . . . . . . 97.6 mt -63.27 -46.93 94.37 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.731 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' D' ' 33' ' ' GLY . . . -64.02 -51.09 56.12 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 120.48 -0.867 . . . . 0.0 111.236 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 30' ' ' SER . . . . . . . . . . . . . 17.8 m -60.8 -38.17 84.47 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 117.22 0.51 . . . . 0.0 110.438 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 31' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -63.76 -43.93 94.96 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 32' ' ' LEU . . . . . . . . . . . . . 80.2 mt -84.3 -11.88 55.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.528 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' D' ' 29' ' ' GLY . . . -85.04 6.46 79.13 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.37 -37.52 87.79 Favored 'General case' 0 N--CA 1.456 -0.138 0 CA-C-N 117.227 0.514 . . . . 0.0 110.776 -179.55 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 35' ' ' SER . . . . . . . . . . . . . 16.3 m -65.63 -36.58 84.11 Favored 'General case' 0 C--O 1.224 -0.26 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.926 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 36' ' ' ILE . . . . . . . . . . . . . 87.7 mt -61.46 -40.81 87.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.062 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 37' ' ' LYS . . . . . . . . . . . . . 53.1 mtpt -55.67 -37.79 68.76 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.89 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.82 -41.6 82.23 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.658 -0.782 . . . . 0.0 111.743 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 39' ' ' PHE . . . . . . . . . . . . . 7.4 m-85 -60.96 -46.57 90.19 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 120.037 -0.665 . . . . 0.0 109.82 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 40' ' ' LYS . . . . . . . . . . . . . 24.4 ttpp -58.73 -46.05 88.25 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.128 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 41' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -61.82 -50.98 70.11 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.253 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.64 -43.97 85.25 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 120.073 -0.651 . . . . 0.0 111.273 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 43' ' ' MET . . . . . . . . . . . . . 18.2 tpp -77.26 13.74 1.09 Allowed 'General case' 0 C--O 1.233 0.205 0 O-C-N 122.035 -0.415 . . . . 0.0 110.31 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 44' ' ' SER . . . . . . . . . . . . . 3.7 m -176.49 72.92 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.407 0 CA-C-O 120.74 0.305 . . . . 0.0 110.655 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 45' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -61.34 -65.51 0.68 Allowed 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.721 -0.218 . . . . 0.0 111.188 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 46' ' ' ASP . . . . . 0.436 ' O ' ' CB ' ' D' ' 47' ' ' GLU . 52.0 t0 46.99 80.18 0.05 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-O 119.288 -0.387 . . . . 0.0 110.008 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 47' ' ' GLU . . . . . 0.441 ' CB ' ' CD ' ' D' ' 48' ' ' PRO . 1.3 mt-10 159.24 -68.83 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.125 0 CA-C-N 117.839 0.29 . . . . 0.0 110.382 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 48' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' D' ' 47' ' ' GLU . 37.0 Cg_endo -61.48 163.91 16.76 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 C-N-CA 121.64 1.56 . . . . 0.0 112.062 -179.533 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 49' ' ' LYS . . . . . . . . . . . . . 87.9 tttt . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.352 -179.979 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 1' ' ' FME . . . . . 0.535 ' C ' ' SD ' ' E' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 2' ' ' GLY . . . . . . . . . . . . . . . 97.51 -22.18 42.15 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -67.56 -45.19 79.38 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 4' ' ' ILE . . . . . 0.449 HG23 ' HE1' ' F' ' 7' ' ' TRP . 97.8 mt -113.87 108.43 25.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 5' ' ' SER . . . . . . . . . . . . . 43.9 t -119.62 123.45 43.92 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.447 0.641 . . . . 0.0 111.719 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 6' ' ' ILE . . . . . 0.407 HG21 HD13 ' E' ' 6' ' ' ILE . 4.9 tt -68.2 -28.31 40.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.466 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 7' ' ' TRP . . . . . . . . . . . . . 39.4 m95 -60.25 -28.87 68.39 Favored 'General case' 0 N--CA 1.463 0.221 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.553 -178.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 8' ' ' GLN . . . . . . . . . . . . . 71.6 mt-30 -59.97 -34.67 73.59 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.089 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 9' ' ' LEU . . . . . 0.63 ' C ' HD23 ' E' ' 9' ' ' LEU . 5.8 tt -69.65 -38.7 77.24 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.545 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 10' ' ' LEU . . . . . 0.424 ' O ' HG23 ' E' ' 14' ' ' VAL . 1.8 mt -60.98 -47.39 86.65 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 122.062 -0.399 . . . . 0.0 110.478 -179.036 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 11' ' ' ILE . . . . . . . . . . . . . 9.9 tt -65.24 -43.08 95.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.115 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 12' ' ' ILE . . . . . . . . . . . . . 37.5 mt -63.73 -44.12 98.23 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.16 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.781 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.05 -40.07 92.25 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.032 -179.491 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 14' ' ' VAL . . . . . 0.424 HG23 ' O ' ' E' ' 10' ' ' LEU . 39.6 t -59.94 -45.4 95.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 15' ' ' ILE . . . . . 0.563 ' O ' ' HG ' ' E' ' 19' ' ' LEU . 71.9 mt -60.81 -44.73 98.16 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 C-N-CA 120.658 -0.417 . . . . 0.0 110.301 179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 16' ' ' VAL . . . . . . . . . . . . . 55.5 t -58.76 -45.56 91.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.802 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 17' ' ' VAL . . . . . 0.572 ' O ' ' N ' ' E' ' 21' ' ' GLY . 95.1 t -63.43 -42.88 97.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.794 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 18' ' ' LEU . . . . . 0.503 HD13 HD12 ' D' ' 19' ' ' LEU . 8.1 mt -65.3 -46.14 81.56 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 120.0 -0.68 . . . . 0.0 111.075 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 19' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' E' ' 15' ' ' ILE . 38.2 mt -64.06 -42.06 97.14 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.369 -179.529 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -89.02 -11.0 45.41 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 179.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 21' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' E' ' 17' ' ' VAL . . . 73.86 176.61 34.21 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -178.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 22' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.08 -38.74 7.6 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 117.633 0.717 . . . . 0.0 111.068 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 23' ' ' LYS . . . . . . . . . . . . . 18.8 tptm -64.09 -46.44 84.24 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.794 179.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 24' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -64.23 -42.09 96.71 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.185 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 25' ' ' LEU . . . . . 0.416 HD23 ' C ' ' E' ' 25' ' ' LEU . 7.3 tt -60.56 -22.71 63.96 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.566 -0.453 . . . . 0.0 110.69 179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 26' ' ' GLY . . . . . . . . . . . . . . . -68.1 -51.16 35.21 Favored Glycine 0 C--N 1.337 0.589 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 27' ' ' SER . . . . . . . . . . . . . 79.4 p -63.31 -41.63 98.95 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 110.371 -0.233 . . . . 0.0 110.371 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 28' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.86 -46.97 94.99 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 C-N-CA 120.388 -0.525 . . . . 0.0 110.722 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.406 ' O ' ' N ' ' E' ' 33' ' ' GLY . . . -64.16 -51.25 54.52 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 120.472 -0.87 . . . . 0.0 111.069 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 30' ' ' SER . . . . . . . . . . . . . 77.7 p -60.6 -38.14 83.69 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 117.17 0.485 . . . . 0.0 110.456 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 31' ' ' ASP . . . . . . . . . . . . . 97.5 m-20 -63.81 -43.55 95.93 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.136 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 32' ' ' LEU . . . . . . . . . . . . . 68.3 mt -84.43 -11.98 55.22 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.503 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 33' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' E' ' 29' ' ' GLY . . . -85.07 6.45 79.21 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.43 -37.32 87.11 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 120.564 -0.454 . . . . 0.0 110.805 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 35' ' ' SER . . . . . . . . . . . . . 15.4 m -65.83 -36.61 83.95 Favored 'General case' 0 C--O 1.222 -0.373 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.733 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 36' ' ' ILE . . . . . . . . . . . . . 89.2 mt -61.49 -40.94 88.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.994 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 37' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -55.6 -37.82 68.6 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.531 -0.467 . . . . 0.0 109.939 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.58 -41.91 82.56 Favored Glycine 0 CA--C 1.524 0.602 0 C-N-CA 120.623 -0.798 . . . . 0.0 111.675 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 39' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -60.8 -46.74 89.35 Favored 'General case' 0 N--CA 1.456 -0.145 0 C-N-CA 119.903 -0.719 . . . . 0.0 109.603 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 40' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -58.73 -45.95 88.49 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.893 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 41' ' ' LYS . . . . . . . . . . . . . 75.2 tttt -61.82 -51.03 69.93 Favored 'General case' 0 C--O 1.227 -0.115 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.393 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.59 -43.86 84.93 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 120.094 -0.642 . . . . 0.0 111.426 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 43' ' ' MET . . . . . . . . . . . . . 18.3 ptp -77.47 14.26 1.03 Allowed 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.428 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 44' ' ' SER . . . . . . . . . . . . . 26.2 t -128.9 -11.26 4.83 Favored 'General case' 0 N--CA 1.469 0.477 0 O-C-N 121.689 -0.632 . . . . 0.0 110.817 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 45' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -66.94 -45.24 78.43 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.381 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 46' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -83.23 43.81 0.9 Allowed 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.348 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 47' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -171.29 88.16 0.47 Allowed Pre-proline 0 N--CA 1.47 0.532 0 C-N-CA 121.053 -0.259 . . . . 0.0 110.757 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 48' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -75.81 158.34 39.03 Favored 'Trans proline' 0 N--CA 1.494 1.501 0 C-N-CA 122.026 1.818 . . . . 0.0 112.309 -179.266 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 49' ' ' LYS . . . . . . . . . . . . . 64.7 mttp . . . . . 0 C--N 1.33 -0.245 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.809 179.795 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 1' ' ' FME . . . . . 0.586 ' N ' ' SD ' ' F' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.55 47.22 0.46 Allowed Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.94 -26.49 0.91 Allowed Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 4' ' ' ILE . . . . . . . . . . . . . 96.6 mt -94.45 103.66 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 5' ' ' SER . . . . . . . . . . . . . 13.2 t -119.54 124.92 47.58 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.606 0.717 . . . . 0.0 111.899 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 6' ' ' ILE . . . . . . . . . . . . . 10.1 tt -67.03 -33.12 61.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.669 177.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 7' ' ' TRP . . . . . 0.449 ' HE1' HG23 ' E' ' 4' ' ' ILE . 50.6 m95 -60.44 -28.88 68.63 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 114.55 -1.204 . . . . 0.0 110.29 -178.628 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 8' ' ' GLN . . . . . . . . . . . . . 65.4 mm-40 -59.97 -34.88 73.88 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.218 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 9' ' ' LEU . . . . . . . . . . . . . 85.8 mt -69.42 -38.7 78.01 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.561 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 10' ' ' LEU . . . . . 0.407 ' O ' HG23 ' F' ' 14' ' ' VAL . 2.2 mt -60.87 -47.43 86.4 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 120.519 -0.473 . . . . 0.0 110.464 -178.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 11' ' ' ILE . . . . . . . . . . . . . 10.1 tt -64.78 -43.64 96.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.162 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 12' ' ' ILE . . . . . . . . . . . . . 80.2 mt -63.72 -44.21 98.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 C-N-CA 120.565 -0.454 . . . . 0.0 110.708 179.101 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.62 -40.22 91.12 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.123 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 14' ' ' VAL . . . . . 0.407 HG23 ' O ' ' F' ' 10' ' ' LEU . 41.8 t -60.07 -45.03 96.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 15' ' ' ILE . . . . . 0.538 ' O ' ' HG ' ' F' ' 19' ' ' LEU . 69.3 mt -60.96 -44.81 98.86 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.581 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.221 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 16' ' ' VAL . . . . . . . . . . . . . 53.6 t -58.59 -45.55 90.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 C-N-CA 120.549 -0.461 . . . . 0.0 111.057 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 17' ' ' VAL . . . . . 0.573 ' O ' ' N ' ' F' ' 21' ' ' GLY . 84.2 t -63.57 -42.63 96.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.991 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 18' ' ' LEU . . . . . . . . . . . . . 4.4 mt -65.48 -45.96 81.64 Favored 'General case' 0 N--CA 1.463 0.212 0 C-N-CA 119.958 -0.697 . . . . 0.0 111.063 -179.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 19' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' F' ' 15' ' ' ILE . 39.1 mt -64.03 -42.04 97.22 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 120.322 -0.551 . . . . 0.0 110.593 -179.577 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -88.86 -10.74 46.9 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 120.73 0.3 . . . . 0.0 110.439 179.077 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 21' ' ' GLY . . . . . 0.573 ' N ' ' O ' ' F' ' 17' ' ' VAL . . . 73.44 176.87 33.28 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -178.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 22' ' ' THR . . . . . . . . . . . . . 81.8 m -102.53 -38.58 7.48 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 117.604 0.702 . . . . 0.0 111.1 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 23' ' ' LYS . . . . . . . . . . . . . 87.8 mttt -63.87 -46.28 85.65 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.13 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 24' ' ' LYS . . . . . . . . . . . . . 67.2 tttt -64.53 -42.15 95.92 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 110.062 -0.348 . . . . 0.0 110.062 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 25' ' ' LEU . . . . . 0.424 ' C ' HD23 ' F' ' 25' ' ' LEU . 6.8 tt -60.44 -22.72 63.75 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.99 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 26' ' ' GLY . . . . . . . . . . . . . . . -68.06 -51.61 32.76 Favored Glycine 0 C--N 1.334 0.464 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 27' ' ' SER . . . . . . . . . . . . . 66.7 m -63.0 -41.48 99.59 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.668 179.367 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 28' ' ' ILE . . . . . . . . . . . . . 90.3 mt -63.06 -47.02 94.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.456 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' F' ' 33' ' ' GLY . . . -64.27 -50.79 57.79 Favored Glycine 0 CA--C 1.528 0.87 0 C-N-CA 120.235 -0.983 . . . . 0.0 111.282 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 30' ' ' SER . . . . . . . . . . . . . 16.2 m -60.61 -38.27 84.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 117.239 0.519 . . . . 0.0 110.376 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 31' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -63.98 -43.74 94.83 Favored 'General case' 0 C--N 1.333 -0.148 0 C-N-CA 120.661 -0.415 . . . . 0.0 110.011 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 32' ' ' LEU . . . . . . . . . . . . . 75.4 mt -84.18 -12.15 55.38 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.339 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 33' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' F' ' 29' ' ' GLY . . . -84.89 6.02 80.25 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.47 -37.28 87.0 Favored 'General case' 0 C--N 1.332 -0.156 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.685 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 35' ' ' SER . . . . . . . . . . . . . 37.8 t -65.77 -36.53 83.8 Favored 'General case' 0 C--O 1.222 -0.38 0 CA-C-O 120.788 0.328 . . . . 0.0 110.794 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 36' ' ' ILE . . . . . . . . . . . . . 85.1 mt -61.42 -41.18 88.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 37' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -55.78 -37.51 68.66 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.52 -0.472 . . . . 0.0 109.91 -179.624 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.83 -41.92 80.93 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.593 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 39' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -60.55 -47.09 87.7 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.053 -0.659 . . . . 0.0 109.651 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 40' ' ' LYS . . . . . . . . . . . . . 55.8 tttp -58.45 -46.17 87.11 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.904 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 41' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -61.98 -50.85 70.44 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.365 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.57 -44.01 84.96 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 120.082 -0.647 . . . . 0.0 111.416 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 43' ' ' MET . . . . . . . . . . . . . 20.3 mtm -77.14 14.35 0.92 Allowed 'General case' 0 C--N 1.333 -0.15 0 O-C-N 122.073 -0.392 . . . . 0.0 110.592 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 44' ' ' SER . . . . . . . . . . . . . 28.8 t -169.27 80.92 0.12 Allowed 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.727 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 45' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -61.81 -45.7 92.69 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.217 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 46' ' ' ASP . . . . . 0.483 ' CG ' ' H ' ' F' ' 47' ' ' GLU . 37.7 t70 -93.93 179.05 5.47 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 121.017 -0.273 . . . . 0.0 110.289 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 47' ' ' GLU . . . . . 0.483 ' H ' ' CG ' ' F' ' 46' ' ' ASP . 16.9 tp10 -173.18 125.16 0.45 Allowed Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 48' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.02 -19.54 26.45 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 121.824 1.683 . . . . 0.0 111.903 -179.098 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 49' ' ' LYS . . . . . . . . . . . . . 17.4 ptpt . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.748 -179.685 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 1' ' ' FME . . . . . 0.533 ' N ' ' SD ' ' G' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.91 166.16 30.45 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . 161.64 -78.96 0.16 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 4' ' ' ILE . . . . . . . . . . . . . 89.7 mt -99.57 112.92 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.681 0.277 . . . . 0.0 110.389 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 5' ' ' SER . . . . . 0.432 ' OG ' ' OE1' ' G' ' 8' ' ' GLN . 35.2 t -119.61 126.26 50.74 Favored 'General case' 0 C--O 1.223 -0.324 0 CA-C-O 121.581 0.705 . . . . 0.0 111.208 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 6' ' ' ILE . . . . . . . . . . . . . 12.1 tt -66.49 -34.22 68.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.113 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 7' ' ' TRP . . . . . . . . . . . . . 45.8 m95 -58.98 -29.12 66.97 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.612 -179.066 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 8' ' ' GLN . . . . . 0.56 ' N ' ' OE1' ' G' ' 8' ' ' GLN . 0.9 OUTLIER -59.52 -35.03 73.4 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.336 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' G' G ' 9' ' ' LEU . . . . . . . . . . . . . 96.1 mt -69.34 -38.75 78.3 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.609 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 10' ' ' LEU . . . . . . . . . . . . . 2.5 mt -60.59 -47.56 85.66 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 122.053 -0.404 . . . . 0.0 110.833 -179.292 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 11' ' ' ILE . . . . . . . . . . . . . 10.9 tt -65.1 -43.31 95.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.145 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 12' ' ' ILE . . . . . . . . . . . . . 40.4 mt -63.5 -44.34 98.72 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.076 0 C-N-CA 120.944 -0.303 . . . . 0.0 110.808 178.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.0 -39.76 90.95 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.294 -179.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 14' ' ' VAL . . . . . . . . . . . . . 25.1 t -60.14 -44.83 96.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 15' ' ' ILE . . . . . 0.514 ' O ' ' HG ' ' G' ' 19' ' ' LEU . 69.8 mt -61.41 -44.66 98.91 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.897 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.236 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 16' ' ' VAL . . . . . . . . . . . . . 60.1 t -58.53 -45.77 90.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.758 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 17' ' ' VAL . . . . . 0.581 ' O ' ' N ' ' G' ' 21' ' ' GLY . 92.0 t -63.18 -43.14 98.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.93 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 18' ' ' LEU . . . . . . . . . . . . . 93.9 mt -65.04 -46.21 82.23 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.039 -179.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 19' ' ' LEU . . . . . 0.551 HD12 HD13 ' H' ' 18' ' ' LEU . 52.5 mt -63.9 -42.43 97.43 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 120.724 -0.391 . . . . 0.0 110.345 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -88.55 -11.07 46.71 Favored 'General case' 0 N--CA 1.47 0.556 0 O-C-N 122.33 -0.231 . . . . 0.0 110.464 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 21' ' ' GLY . . . . . 0.581 ' N ' ' O ' ' G' ' 17' ' ' VAL . . . 73.85 176.75 34.44 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -178.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 22' ' ' THR . . . . . . . . . . . . . 18.9 m -102.36 -38.78 7.46 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 117.654 0.727 . . . . 0.0 110.945 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 23' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -63.81 -46.53 84.72 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 120.431 -0.508 . . . . 0.0 110.947 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 24' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -64.49 -41.86 96.2 Favored 'General case' 0 C--N 1.336 -0.015 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.09 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 25' ' ' LEU . . . . . 0.423 ' C ' HD23 ' G' ' 25' ' ' LEU . 7.0 tt -60.71 -22.6 64.13 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 120.529 -0.468 . . . . 0.0 110.888 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 26' ' ' GLY . . . . . . . . . . . . . . . -68.13 -51.32 34.06 Favored Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.596 -1.002 . . . . 0.0 110.596 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 27' ' ' SER . . . . . . . . . . . . . 78.2 p -63.03 -41.35 99.51 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 121.015 -0.274 . . . . 0.0 110.827 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 28' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.37 -46.72 94.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.695 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.4 ' O ' ' N ' ' G' ' 33' ' ' GLY . . . -64.2 -50.83 57.69 Favored Glycine 0 CA--C 1.529 0.931 0 C-N-CA 120.424 -0.894 . . . . 0.0 111.189 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 30' ' ' SER . . . . . . . . . . . . . 22.5 m -60.83 -38.43 85.44 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 117.255 0.528 . . . . 0.0 110.353 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 31' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -63.6 -43.73 96.07 Favored 'General case' 0 C--N 1.332 -0.17 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.121 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 32' ' ' LEU . . . . . . . . . . . . . 74.7 mt -84.52 -11.57 55.84 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.296 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' G' ' 29' ' ' GLY . . . -85.34 6.4 79.96 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.111 -0.795 . . . . 0.0 111.111 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 34' ' ' ALA . . . . . 0.489 ' O ' ' HG3' ' G' ' 37' ' ' LYS . . . -64.35 -37.49 87.68 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 117.148 0.474 . . . . 0.0 110.841 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -65.86 -36.28 83.01 Favored 'General case' 0 C--O 1.226 -0.141 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.79 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 36' ' ' ILE . . . . . . . . . . . . . 82.0 mt -61.77 -40.64 87.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 37' ' ' LYS . . . . . 0.489 ' HG3' ' O ' ' G' ' 34' ' ' ALA . 0.0 OUTLIER -55.94 -37.48 69.04 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.879 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' G' G ' 38' ' ' GLY . . . . . 0.451 ' N ' ' HG3' ' G' ' 37' ' ' LYS . . . -68.89 -41.98 80.27 Favored Glycine 0 CA--C 1.524 0.597 0 C-N-CA 120.579 -0.82 . . . . 0.0 111.647 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 39' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -60.56 -46.79 88.88 Favored 'General case' 0 C--N 1.334 -0.088 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.69 179.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 40' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -58.73 -45.84 88.73 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.121 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 41' ' ' LYS . . . . . . . . . . . . . 47.1 mmtt -61.83 -51.13 69.48 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.266 -179.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.73 -43.78 85.53 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.381 -179.664 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 43' ' ' MET . . . . . 0.425 ' O ' ' OD1' ' G' ' 46' ' ' ASP . 3.4 mtm -77.32 15.21 0.79 Allowed 'General case' 0 N--CA 1.456 -0.167 0 O-C-N 122.075 -0.391 . . . . 0.0 110.405 179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 44' ' ' SER . . . . . . . . . . . . . 84.0 p -71.78 -10.93 60.5 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 111.596 0.221 . . . . 0.0 111.596 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 45' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -61.54 -45.02 95.95 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.841 -0.344 . . . . 0.0 111.11 -179.218 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 46' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' G' ' 43' ' ' MET . 41.4 p30 -90.02 45.94 1.31 Allowed 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 121.216 -0.193 . . . . 0.0 110.772 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 47' ' ' GLU . . . . . . . . . . . . . 73.5 mt-10 -151.71 94.48 3.37 Favored Pre-proline 0 CA--C 1.536 0.406 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 48' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -53.34 140.81 62.19 Favored 'Trans proline' 0 N--CA 1.498 1.764 0 C-N-CA 122.204 1.936 . . . . 0.0 112.216 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 49' ' ' LYS . . . . . . . . . . . . . 27.5 mmtp . . . . . 0 C--N 1.327 -0.385 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.344 -178.931 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.15 161.72 29.4 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 111.061 -0.815 . . . . 0.0 111.061 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -163.29 149.75 17.69 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 4' ' ' ILE . . . . . . . . . . . . . 50.6 mt 38.99 67.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 120.802 0.334 . . . . 0.0 110.317 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 5' ' ' SER . . . . . . . . . . . . . 18.3 t -117.2 129.67 56.09 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.301 0.572 . . . . 0.0 111.736 -178.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 6' ' ' ILE . . . . . . . . . . . . . 14.3 tt -65.68 -32.32 57.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.481 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 7' ' ' TRP . . . . . . . . . . . . . 46.1 m95 -56.92 -28.62 62.24 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.128 -1.397 . . . . 0.0 110.431 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 8' ' ' GLN . . . . . . . . . . . . . 52.9 mt-30 -60.04 -34.72 73.77 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.389 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 9' ' ' LEU . . . . . . . . . . . . . 36.2 mt -69.76 -38.49 76.78 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.534 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 10' ' ' LEU . . . . . . . . . . . . . 2.9 mt -60.76 -47.66 85.31 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.376 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 11' ' ' ILE . . . . . . . . . . . . . 10.5 tt -64.92 -43.39 96.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.111 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 12' ' ' ILE . . . . . . . . . . . . . 40.7 mt -63.83 -43.87 97.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.791 179.016 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.83 -40.32 92.34 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.077 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 14' ' ' VAL . . . . . . . . . . . . . 24.8 t -59.77 -45.42 94.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 15' ' ' ILE . . . . . 0.56 ' O ' ' HG ' ' H' ' 19' ' ' LEU . 74.2 mt -61.12 -44.61 98.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.64 0 C-N-CA 120.375 -0.53 . . . . 0.0 110.167 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 16' ' ' VAL . . . . . . . . . . . . . 41.8 t -58.69 -45.42 90.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 O-C-N 121.957 -0.464 . . . . 0.0 110.987 179.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 17' ' ' VAL . . . . . 0.576 ' O ' ' N ' ' H' ' 21' ' ' GLY . 84.0 t -63.53 -42.82 97.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.942 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 18' ' ' LEU . . . . . 0.551 HD13 HD12 ' G' ' 19' ' ' LEU . 4.8 mt -65.56 -45.83 81.83 Favored 'General case' 0 N--CA 1.465 0.285 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.009 -179.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 19' ' ' LEU . . . . . 0.56 ' HG ' ' O ' ' H' ' 15' ' ' ILE . 28.9 mt -64.04 -42.16 97.15 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.518 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -89.05 -10.81 46.08 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 21' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' H' ' 17' ' ' VAL . . . 73.72 176.66 33.82 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.303 -1.519 . . . . 0.0 109.303 -178.844 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 22' ' ' THR . . . . . . . . . . . . . 29.6 m -102.05 -38.67 7.64 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 117.408 0.604 . . . . 0.0 111.289 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 23' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -63.89 -46.49 84.64 Favored 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 120.523 -0.471 . . . . 0.0 110.781 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 24' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -64.31 -42.06 96.52 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.027 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 25' ' ' LEU . . . . . 0.409 HD23 ' C ' ' H' ' 25' ' ' LEU . 8.0 tt -60.83 -22.75 64.51 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.874 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.93 -51.32 35.24 Favored Glycine 0 C--N 1.334 0.436 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 27' ' ' SER . . . . . . . . . . . . . 78.2 p -63.12 -41.29 99.32 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.819 179.251 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 28' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.28 -46.89 94.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 C-N-CA 120.498 -0.481 . . . . 0.0 110.699 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' H' ' 33' ' ' GLY . . . -64.32 -50.54 59.18 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 120.16 -1.019 . . . . 0.0 111.437 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 30' ' ' SER . . . . . . . . . . . . . 15.8 m -61.07 -37.98 84.59 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 117.322 0.561 . . . . 0.0 110.455 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 31' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -64.01 -43.62 95.06 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.262 179.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -84.28 -11.86 55.69 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.391 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' H' ' 29' ' ' GLY . . . -85.24 6.59 79.09 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.41 -37.35 87.21 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.744 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -65.85 -36.68 84.13 Favored 'General case' 0 C--O 1.222 -0.357 0 C-N-CA 120.985 -0.286 . . . . 0.0 110.491 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 36' ' ' ILE . . . . . . . . . . . . . 90.2 mt -61.4 -41.01 88.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 37' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -55.49 -37.82 68.33 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.911 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.9 -41.69 81.37 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 120.251 -0.975 . . . . 0.0 111.592 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 39' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -60.99 -46.62 90.02 Favored 'General case' 0 C--N 1.333 -0.126 0 C-N-CA 119.912 -0.715 . . . . 0.0 109.518 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 40' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -58.71 -46.09 88.1 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.034 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 41' ' ' LYS . . . . . . . . . . . . . 27.5 tptp -61.86 -50.89 70.44 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.298 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.71 -43.8 85.48 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 120.017 -0.673 . . . . 0.0 111.377 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 43' ' ' MET . . . . . . . . . . . . . 19.7 mtm -77.26 14.46 0.93 Allowed 'General case' 0 N--CA 1.463 0.212 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.275 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 44' ' ' SER . . . . . . . . . . . . . 22.6 t -138.9 44.32 2.05 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 120.727 0.299 . . . . 0.0 110.851 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 45' ' ' ASP . . . . . 0.585 ' C ' ' H ' ' H' ' 47' ' ' GLU . 40.7 t0 -62.72 -43.09 99.71 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.673 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 46' ' ' ASP . . . . . . . . . . . . . 41.2 t0 62.95 -25.94 0.06 Allowed 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 47' ' ' GLU . . . . . 0.585 ' H ' ' C ' ' H' ' 45' ' ' ASP . 7.1 pt-20 -175.62 158.76 1.98 Allowed Pre-proline 0 CA--C 1.537 0.474 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 48' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.23 -39.27 81.29 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 121.689 1.593 . . . . 0.0 112.185 178.472 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 49' ' ' LYS . . . . . . . . . . . . . 66.1 tttm . . . . . 0 C--N 1.331 -0.21 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.612 -179.98 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.7 -121.64 0.86 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 3' ' ' GLY . . . . . . . . . . . . . . . 92.14 -6.89 78.83 Favored Glycine 0 N--CA 1.467 0.714 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 4' ' ' ILE . . . . . 0.877 HD13 ' H ' ' I' ' 4' ' ' ILE . 0.1 OUTLIER -130.83 166.59 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 -179.569 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' I' I ' 5' ' ' SER . . . . . 0.537 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 0.3 OUTLIER -138.81 82.29 1.89 Allowed 'General case' 0 CA--C 1.533 0.311 0 CA-C-O 121.473 0.654 . . . . 0.0 110.639 179.536 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' I' I ' 6' ' ' ILE . . . . . . . . . . . . . 34.2 mm -71.36 -43.45 73.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.395 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 7' ' ' TRP . . . . . . . . . . . . . 20.5 m95 -54.92 -29.04 55.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.725 -178.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 8' ' ' GLN . . . . . 0.52 ' OE1' ' N ' ' I' ' 8' ' ' GLN . 1.4 mp0 -59.95 -34.74 73.67 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.379 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 9' ' ' LEU . . . . . . . . . . . . . 92.3 mt -69.62 -38.59 77.3 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.588 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 10' ' ' LEU . . . . . 0.532 ' N ' HD12 ' I' ' 10' ' ' LEU . 9.6 mp -60.82 -47.33 86.82 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.77 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 11' ' ' ILE . . . . . 0.483 HG22 ' O ' ' I' ' 8' ' ' GLN . 9.5 tt -64.95 -43.65 96.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 C-N-CA 120.749 -0.38 . . . . 0.0 109.984 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 12' ' ' ILE . . . . . 0.598 ' CG2' HG11 ' A' ' 14' ' ' VAL . 1.4 mm -63.59 -43.94 98.4 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.727 179.171 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.13 -40.03 92.27 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.208 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 14' ' ' VAL . . . . . . . . . . . . . 22.6 t -60.01 -44.97 95.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 15' ' ' ILE . . . . . 0.506 ' O ' ' HG ' ' I' ' 19' ' ' LEU . 7.0 mm -61.01 -44.8 98.98 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.702 0 C-N-CA 120.653 -0.419 . . . . 0.0 110.188 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 16' ' ' VAL . . . . . . . . . . . . . 49.5 t -58.69 -45.49 90.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 C-N-CA 120.456 -0.498 . . . . 0.0 111.09 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 17' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' I' ' 21' ' ' GLY . 91.9 t -63.36 -42.87 97.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.947 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 18' ' ' LEU . . . . . 0.401 HD13 HD12 ' H' ' 19' ' ' LEU . 10.3 mt -65.34 -46.09 81.64 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 119.974 -0.69 . . . . 0.0 110.94 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 19' ' ' LEU . . . . . 0.506 ' HG ' ' O ' ' I' ' 15' ' ' ILE . 48.3 mt -63.95 -42.43 97.3 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 120.839 -0.344 . . . . 0.0 110.278 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 32.6 m-85 -88.82 -10.71 47.1 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.7 0.286 . . . . 0.0 110.583 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 21' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' I' ' 17' ' ' VAL . . . 73.82 176.51 33.9 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.052 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 22' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.19 -38.77 7.54 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 117.536 0.668 . . . . 0.0 110.908 -179.741 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 23' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -64.09 -46.71 83.06 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.531 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 24' ' ' LYS . . . . . . . . . . . . . 16.9 tptp -64.35 -42.08 96.42 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 110.005 -0.369 . . . . 0.0 110.005 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 25' ' ' LEU . . . . . . . . . . . . . 6.5 tt -60.73 -22.48 64.04 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.801 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 26' ' ' GLY . . . . . . . . . . . . . . . -68.05 -51.42 33.99 Favored Glycine 0 C--N 1.334 0.465 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 27' ' ' SER . . . . . . . . . . . . . 42.9 m -62.89 -41.76 99.53 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.666 179.348 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 28' ' ' ILE . . . . . . . . . . . . . 91.5 mt -63.07 -46.92 94.89 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 C-N-CA 120.586 -0.445 . . . . 0.0 110.546 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' I' ' 33' ' ' GLY . . . -64.03 -51.26 54.73 Favored Glycine 0 CA--C 1.53 1.001 0 C-N-CA 120.549 -0.834 . . . . 0.0 111.193 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 30' ' ' SER . . . . . . . . . . . . . 77.4 p -60.46 -38.42 84.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 117.068 0.434 . . . . 0.0 110.298 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 31' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -63.91 -43.53 95.66 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.185 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 32' ' ' LEU . . . . . . . . . . . . . 71.2 mt -84.32 -11.86 55.62 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.489 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' I' ' 29' ' ' GLY . . . -85.21 6.68 78.7 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.39 -37.63 88.19 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 117.006 0.403 . . . . 0.0 110.712 -179.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -65.67 -36.53 83.93 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.901 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 36' ' ' ILE . . . . . . . . . . . . . 86.6 mt -61.56 -40.98 88.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 37' ' ' LYS . . . . . . . . . . . . . 55.0 mtpt -55.64 -37.65 68.5 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.384 -0.526 . . . . 0.0 110.074 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.59 -42.09 81.94 Favored Glycine 0 C--N 1.334 0.434 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.634 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 39' ' ' PHE . . . . . 0.427 ' CD1' ' C ' ' I' ' 39' ' ' PHE . 18.7 t80 -60.62 -46.93 88.42 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.146 -0.622 . . . . 0.0 109.554 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 40' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -58.72 -46.0 88.32 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.889 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 41' ' ' LYS . . . . . . . . . . . . . 66.2 tttm -61.8 -51.04 69.92 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.24 -179.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.65 -43.84 85.2 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.404 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 43' ' ' MET . . . . . . . . . . . . . 16.3 ttp -77.14 17.68 0.44 Allowed 'General case' 0 C--O 1.233 0.211 0 C-N-CA 120.829 -0.348 . . . . 0.0 110.442 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 44' ' ' SER . . . . . . . . . . . . . 17.9 m -136.6 -4.89 2.01 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 178.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 45' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -64.61 -46.68 81.6 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.064 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 46' ' ' ASP . . . . . 0.536 ' OD1' ' N ' ' I' ' 47' ' ' GLU . 1.2 p30 -40.41 -51.94 2.79 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 120.896 -0.322 . . . . 0.0 111.142 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 47' ' ' GLU . . . . . 0.536 ' N ' ' OD1' ' I' ' 46' ' ' ASP . 2.1 tm-20 -178.41 117.69 0.24 Allowed Pre-proline 0 CA--C 1.546 0.82 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.376 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 48' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -74.69 -14.38 21.93 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 121.672 1.581 . . . . 0.0 112.022 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 49' ' ' LYS . . . . . . . . . . . . . 99.1 mttt . . . . . 0 N--CA 1.465 0.288 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.502 -179.566 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' FME . . . . . 0.497 ' SD ' ' N ' ' A' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.16 175.51 44.13 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 82.83 14.07 76.3 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.3 tt -136.21 149.66 27.52 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.78 0.324 . . . . 0.0 110.474 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.411 ' O ' ' OE1' ' A' ' 8' ' ' GLN . 0.4 OUTLIER 49.37 18.85 0.29 Allowed 'General case' 0 C--O 1.222 -0.346 0 CA-C-O 120.946 0.403 . . . . 0.0 110.276 -179.59 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.6 pt -49.49 -32.15 6.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-O 121.164 0.507 . . . . 0.0 109.796 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.537 ' CH2' ' O ' ' I' ' 5' ' ' SER . 35.5 m95 -60.44 -28.91 68.66 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.443 -179.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.411 ' OE1' ' O ' ' A' ' 5' ' ' SER . 9.7 mp0 -60.03 -34.52 73.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.025 0.44 . . . . 0.0 110.328 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.8 tt -69.9 -38.57 76.36 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.454 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.513 ' O ' HG23 ' A' ' 14' ' ' VAL . 6.1 mp -60.69 -47.44 86.26 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.773 -179.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.4 tt -64.89 -43.59 96.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.171 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 34.1 mt -63.68 -44.21 98.35 Favored 'Isoleucine or valine' 0 C--N 1.343 0.296 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.667 179.112 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.82 -39.96 90.98 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.239 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.598 HG11 ' CG2' ' I' ' 12' ' ' ILE . 41.8 t -60.22 -44.82 96.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 C-N-CA 120.69 -0.404 . . . . 0.0 109.967 179.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.8 mt -61.28 -44.52 98.58 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.574 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.198 179.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.1 t -58.86 -45.4 91.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.498 -0.481 . . . . 0.0 110.853 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.573 ' O ' ' N ' ' A' ' 21' ' ' GLY . 77.1 t -63.36 -43.08 98.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.876 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 46.5 mt -65.08 -46.64 80.3 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 121.722 -0.611 . . . . 0.0 110.854 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 77.6 mt -63.65 -42.22 98.12 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.546 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -89.16 -10.74 46.06 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.312 179.235 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.573 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 73.82 176.72 34.31 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.091 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.445 HG23 ' N ' ' A' ' 23' ' ' LYS . 9.5 t -102.02 -39.17 7.44 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 117.752 0.776 . . . . 0.0 111.043 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.445 ' N ' HG23 ' A' ' 22' ' ' THR . 38.7 ttmt -63.84 -46.47 84.9 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.835 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -64.46 -41.93 96.23 Favored 'General case' 0 C--O 1.227 -0.119 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.081 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 6.8 tt -60.61 -22.81 64.17 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.939 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.73 -51.73 33.79 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 77.9 p -62.89 -41.48 99.43 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.753 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 96.7 mt -62.78 -47.43 92.91 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.746 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.406 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -64.07 -50.97 57.02 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.238 -0.982 . . . . 0.0 111.437 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.4 m -60.66 -38.21 84.12 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 117.207 0.503 . . . . 0.0 110.403 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -63.75 -43.46 96.38 Favored 'General case' 0 C--N 1.33 -0.26 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.297 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 66.9 mt -84.59 -12.05 54.82 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.261 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -85.19 6.98 77.58 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 120.657 -0.783 . . . . 0.0 111.268 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.72 -37.33 87.24 Favored 'General case' 0 C--N 1.331 -0.21 0 O-C-N 122.444 -0.445 . . . . 0.0 110.778 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 68.7 p -65.7 -36.68 84.33 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-O 120.907 0.384 . . . . 0.0 110.782 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 90.4 mt -61.36 -40.88 87.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.072 179.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -55.84 -37.6 68.94 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 120.511 -0.476 . . . . 0.0 109.836 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.72 -41.87 81.82 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.764 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.484 ' O ' ' SD ' ' A' ' 43' ' ' MET . 7.6 m-85 -60.83 -46.78 89.23 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 119.936 -0.706 . . . . 0.0 109.549 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -58.57 -46.14 87.53 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.071 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -61.68 -51.04 70.08 Favored 'General case' 0 N--CA 1.457 -0.124 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.407 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.59 -43.91 84.97 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.313 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.531 ' SD ' ' N ' ' A' ' 43' ' ' MET . 0.0 OUTLIER -77.24 17.09 0.5 Allowed 'General case' 0 CA--C 1.531 0.223 0 O-C-N 122.206 -0.308 . . . . 0.0 110.224 179.981 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 78.5 p -71.54 -15.53 62.29 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 120.823 0.344 . . . . 0.0 110.475 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 36.2 p-10 -60.96 -42.18 97.77 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.019 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.519 ' N ' ' OD1' ' A' ' 45' ' ' ASP . 92.4 m-20 -109.28 52.3 0.72 Allowed 'General case' 0 N--CA 1.469 0.483 0 O-C-N 122.461 -0.149 . . . . 0.0 110.806 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -175.89 96.14 0.26 Allowed Pre-proline 0 CA--C 1.535 0.388 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -76.25 150.38 32.88 Favored 'Trans proline' 0 N--CA 1.491 1.326 0 C-N-CA 121.787 1.658 . . . . 0.0 112.078 -179.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 98.9 mttt . . . . . 0 N--CA 1.464 0.238 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.458 -179.954 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' FME . . . . . 0.593 ' N ' ' SD ' ' B' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.0 98.22 0.13 Allowed Glycine 0 CA--C 1.526 0.734 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -64.66 -39.21 96.54 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' ILE . . . . . . . . . . . . . 80.0 mt -68.86 86.1 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 40.1 t -117.59 124.16 47.98 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 121.227 0.537 . . . . 0.0 111.313 -179.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' ILE . . . . . . . . . . . . . 16.7 tt -67.64 -32.53 57.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.373 -0.831 . . . . 0.0 109.389 178.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' TRP . . . . . . . . . . . . . 48.4 m95 -62.61 -28.79 70.14 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.564 -178.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' GLN . . . . . . . . . . . . . 56.7 mm-40 -60.08 -34.99 74.2 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 96.8 mt -69.41 -38.58 77.99 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.629 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.418 ' O ' HG23 ' B' ' 14' ' ' VAL . 2.2 mt -61.14 -47.55 85.73 Favored 'General case' 0 N--CA 1.468 0.455 0 O-C-N 121.788 -0.57 . . . . 0.0 110.361 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' ILE . . . . . . . . . . . . . 9.5 tt -65.01 -43.46 96.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.049 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 52.3 mt -63.77 -43.62 98.02 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.933 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.19 -39.98 92.21 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.74 -0.384 . . . . 0.0 110.118 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.418 HG23 ' O ' ' B' ' 10' ' ' LEU . 51.1 t -60.07 -45.01 96.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.492 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 55.3 mt -60.89 -44.75 98.48 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.615 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.321 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' VAL . . . . . . . . . . . . . 48.9 t -58.88 -45.44 91.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.757 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' VAL . . . . . 0.566 ' O ' ' N ' ' B' ' 21' ' ' GLY . 95.2 t -63.52 -42.9 97.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.719 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' LEU . . . . . . . . . . . . . 4.5 mt -65.31 -46.15 81.5 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 119.904 -0.718 . . . . 0.0 111.13 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' B' ' 15' ' ' ILE . 51.7 mt -63.89 -42.11 97.54 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.517 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -88.85 -10.89 46.38 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 110.299 -0.26 . . . . 0.0 110.299 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' B' ' 17' ' ' VAL . . . 73.63 176.57 33.34 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 -178.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.02 -38.78 7.61 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 117.291 0.545 . . . . 0.0 111.152 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -63.82 -46.5 84.82 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.323 -0.551 . . . . 0.0 110.94 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' LYS . . . . . . . . . . . . . 41.7 tptt -64.54 -41.88 96.07 Favored 'General case' 0 N--CA 1.455 -0.221 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.405 ' C ' HD23 ' B' ' 25' ' ' LEU . 7.3 tt -60.33 -22.89 63.75 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.09 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.89 -51.37 35.13 Favored Glycine 0 CA--C 1.523 0.549 0 C-N-CA 120.197 -1.001 . . . . 0.0 110.674 -179.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' SER . . . . . . . . . . . . . 45.2 t -62.95 -41.67 99.59 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.68 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' ILE . . . . . . . . . . . . . 95.4 mt -63.18 -46.68 95.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 120.529 -0.468 . . . . 0.0 110.794 -179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.02 -51.19 55.28 Favored Glycine 0 CA--C 1.526 0.755 0 C-N-CA 120.6 -0.81 . . . . 0.0 111.418 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' SER . . . . . . . . . . . . . 20.0 m -60.64 -38.4 84.68 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 117.09 0.445 . . . . 0.0 110.349 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -63.81 -43.46 96.19 Favored 'General case' 0 C--N 1.331 -0.208 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.168 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 76.7 mt -84.51 -11.83 55.38 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.213 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -85.43 6.86 78.6 Favored Glycine 0 CA--C 1.531 1.059 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.224 -179.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.58 -37.24 86.87 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 120.48 -0.488 . . . . 0.0 110.999 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' SER . . . . . . . . . . . . . 66.4 p -65.83 -36.67 84.11 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.508 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' ILE . . . . . . . . . . . . . 87.5 mt -61.4 -41.24 89.14 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -55.65 -37.73 68.63 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.826 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.73 -42.12 80.84 Favored Glycine 0 CA--C 1.527 0.794 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.514 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -60.11 -47.12 87.21 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 120.212 -0.595 . . . . 0.0 109.826 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 46.2 tptt -58.98 -45.9 89.44 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.857 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' LYS . . . . . . . . . . . . . 45.2 mmtt -61.52 -51.19 69.66 Favored 'General case' 0 C--O 1.227 -0.087 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.374 -179.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.78 -43.71 85.76 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 120.008 -0.677 . . . . 0.0 111.254 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' MET . . . . . . . . . . . . . 2.4 mpp? -77.27 14.0 1.03 Allowed 'General case' 0 C--N 1.331 -0.196 0 O-C-N 122.185 -0.322 . . . . 0.0 110.372 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' SER . . . . . . . . . . . . . 57.7 m -153.66 38.81 0.48 Allowed 'General case' 0 N--CA 1.462 0.169 0 CA-C-O 120.753 0.311 . . . . 0.0 110.75 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -61.4 -42.82 99.33 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.27 -0.423 . . . . 0.0 109.88 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -81.94 44.61 0.85 Allowed 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 121.306 0.574 . . . . 0.0 110.395 179.168 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' GLU . . . . . . . . . . . . . 30.2 tp10 -171.74 88.21 0.45 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.487 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_exo -62.13 147.86 94.28 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 C-N-CA 122.436 2.091 . . . . 0.0 112.059 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt . . . . . 0 N--CA 1.467 0.385 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.297 -179.853 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 2' ' ' GLY . . . . . . . . . . . . . . . 57.93 -112.18 3.64 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -66.82 -176.19 7.57 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 4' ' ' ILE . . . . . . . . . . . . . 80.5 mt 55.38 79.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 5' ' ' SER . . . . . . . . . . . . . 45.4 t -119.8 125.87 49.63 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 121.419 0.628 . . . . 0.0 112.545 -179.026 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 tt -66.3 -32.82 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.271 -0.877 . . . . 0.0 108.744 177.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 7' ' ' TRP . . . . . . . . . . . . . 44.5 m95 -57.14 -28.85 63.1 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.414 -1.267 . . . . 0.0 110.625 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 8' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -59.61 -35.07 73.61 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.854 0.359 . . . . 0.0 110.303 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 9' ' ' LEU . . . . . . . . . . . . . 80.9 mt -69.51 -38.52 77.61 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.771 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 10' ' ' LEU . . . . . . . . . . . . . 3.0 mt -61.05 -47.41 86.48 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.613 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 11' ' ' ILE . . . . . . . . . . . . . 13.2 tt -65.12 -43.22 95.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 120.441 -0.503 . . . . 0.0 110.192 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 12' ' ' ILE . . . . . . . . . . . . . 69.2 mt -63.69 -44.25 98.35 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.498 178.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.97 -40.11 92.17 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 14' ' ' VAL . . . . . . . . . . . . . 25.5 t -59.93 -45.2 95.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 C-N-CA 120.723 -0.391 . . . . 0.0 109.977 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 15' ' ' ILE . . . . . 0.527 ' O ' ' HG ' ' C' ' 19' ' ' LEU . 70.1 mt -60.8 -44.89 98.48 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.722 0 C-N-CA 120.424 -0.511 . . . . 0.0 110.238 179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 16' ' ' VAL . . . . . . . . . . . . . 25.5 t -58.74 -45.46 91.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.94 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 17' ' ' VAL . . . . . 0.583 ' O ' ' N ' ' C' ' 21' ' ' GLY . 71.1 t -63.27 -43.06 98.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 C-N-CA 120.91 -0.316 . . . . 0.0 110.933 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 18' ' ' LEU . . . . . 0.419 HD23 ' HA ' ' C' ' 18' ' ' LEU . 79.9 mt -65.22 -46.19 81.64 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.953 -179.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 19' ' ' LEU . . . . . 0.527 ' HG ' ' O ' ' C' ' 15' ' ' ILE . 45.1 mt -63.83 -42.36 97.66 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.288 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -88.91 -10.78 46.59 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 120.652 0.263 . . . . 0.0 110.317 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 21' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' C' ' 17' ' ' VAL . . . 73.64 176.54 33.33 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -178.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 22' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.0 -38.79 7.61 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 117.333 0.567 . . . . 0.0 111.168 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 23' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -63.88 -46.76 83.47 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.801 179.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 24' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -64.36 -41.85 96.51 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.896 0.379 . . . . 0.0 110.122 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 25' ' ' LEU . . . . . . . . . . . . . 7.3 tt -60.46 -23.05 64.14 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.93 179.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.89 -51.34 35.26 Favored Glycine 0 C--N 1.334 0.451 0 C-N-CA 120.208 -0.996 . . . . 0.0 110.683 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 27' ' ' SER . . . . . . . . . . . . . 77.8 p -62.86 -41.69 99.47 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 121.141 -0.223 . . . . 0.0 110.664 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 28' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.94 -47.0 94.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 C-N-CA 120.469 -0.492 . . . . 0.0 110.632 -179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.406 ' O ' ' N ' ' C' ' 33' ' ' GLY . . . -64.34 -50.87 57.15 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.173 -179.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 30' ' ' SER . . . . . . . . . . . . . 24.8 m -60.62 -38.51 84.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 117.332 0.566 . . . . 0.0 110.404 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 31' ' ' ASP . . . . . . . . . . . . . 75.2 m-20 -63.67 -43.65 96.08 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.114 179.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 32' ' ' LEU . . . . . . . . . . . . . 73.3 mt -84.48 -11.86 55.37 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.362 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' C' ' 29' ' ' GLY . . . -85.14 6.55 79.01 Favored Glycine 0 CA--C 1.528 0.844 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.41 -37.43 87.48 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.735 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 35' ' ' SER . . . . . . . . . . . . . 15.5 m -65.63 -36.79 84.73 Favored 'General case' 0 C--O 1.22 -0.482 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.837 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 87.1 mt -61.3 -41.09 88.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.049 179.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 37' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -55.51 -37.72 68.25 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.834 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.86 -42.03 80.27 Favored Glycine 0 CA--C 1.523 0.584 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.597 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 39' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -60.62 -46.89 88.59 Favored 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 119.93 -0.708 . . . . 0.0 109.715 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 40' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -58.68 -45.86 88.53 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.059 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 41' ' ' LYS . . . . . . . . . . . . . 40.2 tttp -61.87 -50.96 70.14 Favored 'General case' 0 C--O 1.224 -0.273 0 CA-C-N 116.532 -0.303 . . . . 0.0 111.363 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.71 -43.98 85.59 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 120.056 -0.658 . . . . 0.0 111.237 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 43' ' ' MET . . . . . . . . . . . . . 33.8 ttm -77.21 14.39 0.93 Allowed 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.472 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 44' ' ' SER . . . . . . . . . . . . . 12.7 p -134.01 -28.96 1.32 Allowed 'General case' 0 N--CA 1.47 0.543 0 O-C-N 121.755 -0.59 . . . . 0.0 110.952 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 45' ' ' ASP . . . . . 0.415 ' O ' ' OD1' ' C' ' 46' ' ' ASP . 31.0 t70 -59.32 -48.26 82.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.758 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 46' ' ' ASP . . . . . 0.415 ' OD1' ' O ' ' C' ' 45' ' ' ASP . 5.8 p-10 39.0 54.94 2.09 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.616 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 47' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -170.1 87.75 0.55 Allowed Pre-proline 0 N--CA 1.465 0.322 0 N-CA-C 110.414 -0.217 . . . . 0.0 110.414 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 48' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -76.52 157.0 36.51 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.852 1.701 . . . . 0.0 112.321 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 49' ' ' LYS . . . . . . . . . . . . . 54.0 mttp . . . . . 0 C--N 1.332 -0.164 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.43 179.994 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 2' ' ' GLY . . . . . . . . . . . . . . . -64.2 145.51 49.69 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.799 -0.921 . . . . 0.0 110.799 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -82.9 -71.48 1.31 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 4' ' ' ILE . . . . . . . . . . . . . 75.8 mt 40.5 77.72 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-O 120.835 0.35 . . . . 0.0 110.138 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 5' ' ' SER . . . . . . . . . . . . . 4.1 t -114.78 131.42 56.8 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.632 0.729 . . . . 0.0 111.571 -178.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 6' ' ' ILE . . . . . . . . . . . . . 5.2 tt -66.03 -25.35 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.308 179.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 7' ' ' TRP . . . . . 0.438 ' HA ' HD12 ' D' ' 10' ' ' LEU . 34.9 m95 -62.07 -28.87 69.91 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 117.023 -1.871 . . . . 0.0 110.635 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 8' ' ' GLN . . . . . 0.646 ' OE1' ' N ' ' D' ' 8' ' ' GLN . 6.8 mp0 -60.12 -34.71 73.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.069 0.462 . . . . 0.0 110.178 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 9' ' ' LEU . . . . . 0.601 ' C ' HD23 ' D' ' 9' ' ' LEU . 5.0 tt -69.65 -38.63 77.21 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.513 179.702 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 10' ' ' LEU . . . . . 0.438 HD12 ' HA ' ' D' ' 7' ' ' TRP . 3.8 mt -61.02 -47.16 87.71 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 120.446 -0.502 . . . . 0.0 110.721 -179.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 11' ' ' ILE . . . . . . . . . . . . . 11.0 tt -65.11 -43.32 95.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.001 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 12' ' ' ILE . . . . . . . . . . . . . 44.1 mt -63.73 -44.14 98.23 Favored 'Isoleucine or valine' 0 C--N 1.338 0.09 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.918 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.62 -40.26 91.25 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.27 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 14' ' ' VAL . . . . . 0.635 ' O ' ' HG ' ' D' ' 18' ' ' LEU . 36.0 t -60.02 -44.81 95.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.932 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 15' ' ' ILE . . . . . 0.448 ' O ' ' HG ' ' D' ' 19' ' ' LEU . 38.8 mt -61.19 -44.79 99.05 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.84 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.169 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 16' ' ' VAL . . . . . . . . . . . . . 55.9 t -58.63 -45.48 90.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 C-N-CA 120.543 -0.463 . . . . 0.0 111.004 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 17' ' ' VAL . . . . . 0.575 ' O ' ' N ' ' D' ' 21' ' ' GLY . 74.1 t -63.27 -42.91 98.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 C-N-CA 120.779 -0.369 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 18' ' ' LEU . . . . . 0.635 ' HG ' ' O ' ' D' ' 14' ' ' VAL . 6.6 mt -65.45 -45.96 81.72 Favored 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 120.046 -0.662 . . . . 0.0 110.945 -179.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 19' ' ' LEU . . . . . 0.503 HD12 HD13 ' E' ' 18' ' ' LEU . 56.4 mt -63.81 -42.44 97.67 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.298 -179.48 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.403 ' CE2' HD21 ' E' ' 18' ' ' LEU . 36.2 m-85 -88.99 -10.8 46.27 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-O 120.718 0.294 . . . . 0.0 110.258 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 21' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' D' ' 17' ' ' VAL . . . 73.47 176.62 32.87 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -178.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 22' ' ' THR . . . . . . . . . . . . . 2.6 p -102.21 -38.71 7.56 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 117.466 0.633 . . . . 0.0 111.093 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 23' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -63.67 -46.66 84.56 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.925 179.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 24' ' ' LYS . . . . . . . . . . . . . 64.9 mttp -64.42 -42.1 96.22 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 25' ' ' LEU . . . . . 0.414 ' C ' HD23 ' D' ' 25' ' ' LEU . 7.4 tt -60.33 -23.01 63.89 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 120.502 -0.479 . . . . 0.0 111.126 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.93 -51.31 35.28 Favored Glycine 0 C--N 1.338 0.655 0 C-N-CA 120.205 -0.998 . . . . 0.0 110.864 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 27' ' ' SER . . . . . . . . . . . . . 78.1 p -63.04 -41.19 99.45 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.758 179.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 28' ' ' ILE . . . . . . . . . . . . . 97.6 mt -63.27 -46.93 94.37 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 120.427 -0.509 . . . . 0.0 110.731 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' D' ' 33' ' ' GLY . . . -64.02 -51.09 56.12 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 120.48 -0.867 . . . . 0.0 111.236 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 30' ' ' SER . . . . . . . . . . . . . 17.8 m -60.8 -38.17 84.47 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 117.22 0.51 . . . . 0.0 110.438 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 31' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -63.76 -43.93 94.96 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 32' ' ' LEU . . . . . . . . . . . . . 80.2 mt -84.3 -11.88 55.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.528 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' D' ' 29' ' ' GLY . . . -85.04 6.46 79.13 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.37 -37.52 87.79 Favored 'General case' 0 N--CA 1.456 -0.138 0 CA-C-N 117.227 0.514 . . . . 0.0 110.776 -179.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 35' ' ' SER . . . . . . . . . . . . . 16.3 m -65.63 -36.58 84.11 Favored 'General case' 0 C--O 1.224 -0.26 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.926 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 36' ' ' ILE . . . . . . . . . . . . . 87.7 mt -61.46 -40.81 87.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.062 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 37' ' ' LYS . . . . . . . . . . . . . 53.1 mtpt -55.67 -37.79 68.76 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.89 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.82 -41.6 82.23 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.658 -0.782 . . . . 0.0 111.743 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 39' ' ' PHE . . . . . . . . . . . . . 7.4 m-85 -60.96 -46.57 90.19 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 120.037 -0.665 . . . . 0.0 109.82 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 40' ' ' LYS . . . . . . . . . . . . . 24.4 ttpp -58.73 -46.05 88.25 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.128 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 41' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -61.82 -50.98 70.11 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.253 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.64 -43.97 85.25 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 120.073 -0.651 . . . . 0.0 111.273 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 43' ' ' MET . . . . . . . . . . . . . 18.2 tpp -77.26 13.74 1.09 Allowed 'General case' 0 C--O 1.233 0.205 0 O-C-N 122.035 -0.415 . . . . 0.0 110.31 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 44' ' ' SER . . . . . . . . . . . . . 3.7 m -176.49 72.92 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.407 0 CA-C-O 120.74 0.305 . . . . 0.0 110.655 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 45' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -61.34 -65.51 0.68 Allowed 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.721 -0.218 . . . . 0.0 111.188 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 46' ' ' ASP . . . . . 0.436 ' O ' ' CB ' ' D' ' 47' ' ' GLU . 52.0 t0 46.99 80.18 0.05 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-O 119.288 -0.387 . . . . 0.0 110.008 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 47' ' ' GLU . . . . . 0.441 ' CB ' ' CD ' ' D' ' 48' ' ' PRO . 1.3 mt-10 159.24 -68.83 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.125 0 CA-C-N 117.839 0.29 . . . . 0.0 110.382 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 48' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' D' ' 47' ' ' GLU . 37.0 Cg_endo -61.48 163.91 16.76 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 C-N-CA 121.64 1.56 . . . . 0.0 112.062 -179.533 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 49' ' ' LYS . . . . . . . . . . . . . 87.9 tttt . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.352 -179.979 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 1' ' ' FME . . . . . 0.535 ' C ' ' SD ' ' E' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 2' ' ' GLY . . . . . . . . . . . . . . . 97.51 -22.18 42.15 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -67.56 -45.19 79.38 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 4' ' ' ILE . . . . . 0.449 HG23 ' HE1' ' F' ' 7' ' ' TRP . 97.8 mt -113.87 108.43 25.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 5' ' ' SER . . . . . . . . . . . . . 43.9 t -119.62 123.45 43.92 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.447 0.641 . . . . 0.0 111.719 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 6' ' ' ILE . . . . . 0.407 HG21 HD13 ' E' ' 6' ' ' ILE . 4.9 tt -68.2 -28.31 40.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.466 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 7' ' ' TRP . . . . . . . . . . . . . 39.4 m95 -60.25 -28.87 68.39 Favored 'General case' 0 N--CA 1.463 0.221 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.553 -178.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 8' ' ' GLN . . . . . . . . . . . . . 71.6 mt-30 -59.97 -34.67 73.59 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.089 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 9' ' ' LEU . . . . . 0.63 ' C ' HD23 ' E' ' 9' ' ' LEU . 5.8 tt -69.65 -38.7 77.24 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.545 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 10' ' ' LEU . . . . . 0.424 ' O ' HG23 ' E' ' 14' ' ' VAL . 1.8 mt -60.98 -47.39 86.65 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 122.062 -0.399 . . . . 0.0 110.478 -179.036 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 11' ' ' ILE . . . . . . . . . . . . . 9.9 tt -65.24 -43.08 95.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.115 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 12' ' ' ILE . . . . . . . . . . . . . 37.5 mt -63.73 -44.12 98.23 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.16 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.781 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.05 -40.07 92.25 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.032 -179.491 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 14' ' ' VAL . . . . . 0.424 HG23 ' O ' ' E' ' 10' ' ' LEU . 39.6 t -59.94 -45.4 95.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 15' ' ' ILE . . . . . 0.563 ' O ' ' HG ' ' E' ' 19' ' ' LEU . 71.9 mt -60.81 -44.73 98.16 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 C-N-CA 120.658 -0.417 . . . . 0.0 110.301 179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 16' ' ' VAL . . . . . . . . . . . . . 55.5 t -58.76 -45.56 91.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.802 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 17' ' ' VAL . . . . . 0.572 ' O ' ' N ' ' E' ' 21' ' ' GLY . 95.1 t -63.43 -42.88 97.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.794 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 18' ' ' LEU . . . . . 0.503 HD13 HD12 ' D' ' 19' ' ' LEU . 8.1 mt -65.3 -46.14 81.56 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 120.0 -0.68 . . . . 0.0 111.075 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 19' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' E' ' 15' ' ' ILE . 38.2 mt -64.06 -42.06 97.14 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.369 -179.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -89.02 -11.0 45.41 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 179.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 21' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' E' ' 17' ' ' VAL . . . 73.86 176.61 34.21 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -178.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 22' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.08 -38.74 7.6 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 117.633 0.717 . . . . 0.0 111.068 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 23' ' ' LYS . . . . . . . . . . . . . 18.8 tptm -64.09 -46.44 84.24 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.794 179.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 24' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -64.23 -42.09 96.71 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.185 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 25' ' ' LEU . . . . . 0.416 HD23 ' C ' ' E' ' 25' ' ' LEU . 7.3 tt -60.56 -22.71 63.96 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.566 -0.453 . . . . 0.0 110.69 179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 26' ' ' GLY . . . . . . . . . . . . . . . -68.1 -51.16 35.21 Favored Glycine 0 C--N 1.337 0.589 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 27' ' ' SER . . . . . . . . . . . . . 79.4 p -63.31 -41.63 98.95 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 110.371 -0.233 . . . . 0.0 110.371 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 28' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.86 -46.97 94.99 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 C-N-CA 120.388 -0.525 . . . . 0.0 110.722 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.406 ' O ' ' N ' ' E' ' 33' ' ' GLY . . . -64.16 -51.25 54.52 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 120.472 -0.87 . . . . 0.0 111.069 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 30' ' ' SER . . . . . . . . . . . . . 77.7 p -60.6 -38.14 83.69 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 117.17 0.485 . . . . 0.0 110.456 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 31' ' ' ASP . . . . . . . . . . . . . 97.5 m-20 -63.81 -43.55 95.93 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.136 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 32' ' ' LEU . . . . . . . . . . . . . 68.3 mt -84.43 -11.98 55.22 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.503 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' E' ' 29' ' ' GLY . . . -85.07 6.45 79.21 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.43 -37.32 87.11 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 120.564 -0.454 . . . . 0.0 110.805 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 35' ' ' SER . . . . . . . . . . . . . 15.4 m -65.83 -36.61 83.95 Favored 'General case' 0 C--O 1.222 -0.373 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.733 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 36' ' ' ILE . . . . . . . . . . . . . 89.2 mt -61.49 -40.94 88.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.994 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 37' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -55.6 -37.82 68.6 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 120.531 -0.467 . . . . 0.0 109.939 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.58 -41.91 82.56 Favored Glycine 0 CA--C 1.524 0.602 0 C-N-CA 120.623 -0.798 . . . . 0.0 111.675 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 39' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -60.8 -46.74 89.35 Favored 'General case' 0 N--CA 1.456 -0.145 0 C-N-CA 119.903 -0.719 . . . . 0.0 109.603 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 40' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -58.73 -45.95 88.49 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.893 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 41' ' ' LYS . . . . . . . . . . . . . 75.2 tttt -61.82 -51.03 69.93 Favored 'General case' 0 C--O 1.227 -0.115 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.393 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.59 -43.86 84.93 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 120.094 -0.642 . . . . 0.0 111.426 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 43' ' ' MET . . . . . . . . . . . . . 18.3 ptp -77.47 14.26 1.03 Allowed 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.428 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 44' ' ' SER . . . . . . . . . . . . . 26.2 t -128.9 -11.26 4.83 Favored 'General case' 0 N--CA 1.469 0.477 0 O-C-N 121.689 -0.632 . . . . 0.0 110.817 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 45' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -66.94 -45.24 78.43 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.381 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 46' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -83.23 43.81 0.9 Allowed 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.348 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 47' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -171.29 88.16 0.47 Allowed Pre-proline 0 N--CA 1.47 0.532 0 C-N-CA 121.053 -0.259 . . . . 0.0 110.757 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 48' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -75.81 158.34 39.03 Favored 'Trans proline' 0 N--CA 1.494 1.501 0 C-N-CA 122.026 1.818 . . . . 0.0 112.309 -179.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 49' ' ' LYS . . . . . . . . . . . . . 64.7 mttp . . . . . 0 C--N 1.33 -0.245 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.809 179.795 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 1' ' ' FME . . . . . 0.586 ' N ' ' SD ' ' F' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.55 47.22 0.46 Allowed Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.94 -26.49 0.91 Allowed Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 4' ' ' ILE . . . . . . . . . . . . . 96.6 mt -94.45 103.66 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 5' ' ' SER . . . . . . . . . . . . . 13.2 t -119.54 124.92 47.58 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.606 0.717 . . . . 0.0 111.899 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 6' ' ' ILE . . . . . . . . . . . . . 10.1 tt -67.03 -33.12 61.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.669 177.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 7' ' ' TRP . . . . . 0.449 ' HE1' HG23 ' E' ' 4' ' ' ILE . 50.6 m95 -60.44 -28.88 68.63 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 114.55 -1.204 . . . . 0.0 110.29 -178.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 8' ' ' GLN . . . . . . . . . . . . . 65.4 mm-40 -59.97 -34.88 73.88 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.218 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 9' ' ' LEU . . . . . . . . . . . . . 85.8 mt -69.42 -38.7 78.01 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.561 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 10' ' ' LEU . . . . . 0.407 ' O ' HG23 ' F' ' 14' ' ' VAL . 2.2 mt -60.87 -47.43 86.4 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 120.519 -0.473 . . . . 0.0 110.464 -178.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 11' ' ' ILE . . . . . . . . . . . . . 10.1 tt -64.78 -43.64 96.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.162 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 12' ' ' ILE . . . . . . . . . . . . . 80.2 mt -63.72 -44.21 98.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 C-N-CA 120.565 -0.454 . . . . 0.0 110.708 179.101 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.62 -40.22 91.12 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.123 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 14' ' ' VAL . . . . . 0.407 HG23 ' O ' ' F' ' 10' ' ' LEU . 41.8 t -60.07 -45.03 96.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 15' ' ' ILE . . . . . 0.538 ' O ' ' HG ' ' F' ' 19' ' ' LEU . 69.3 mt -60.96 -44.81 98.86 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.581 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.221 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 16' ' ' VAL . . . . . . . . . . . . . 53.6 t -58.59 -45.55 90.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 C-N-CA 120.549 -0.461 . . . . 0.0 111.057 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 17' ' ' VAL . . . . . 0.573 ' O ' ' N ' ' F' ' 21' ' ' GLY . 84.2 t -63.57 -42.63 96.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.991 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 18' ' ' LEU . . . . . . . . . . . . . 4.4 mt -65.48 -45.96 81.64 Favored 'General case' 0 N--CA 1.463 0.212 0 C-N-CA 119.958 -0.697 . . . . 0.0 111.063 -179.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 19' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' F' ' 15' ' ' ILE . 39.1 mt -64.03 -42.04 97.22 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 120.322 -0.551 . . . . 0.0 110.593 -179.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -88.86 -10.74 46.9 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 120.73 0.3 . . . . 0.0 110.439 179.077 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 21' ' ' GLY . . . . . 0.573 ' N ' ' O ' ' F' ' 17' ' ' VAL . . . 73.44 176.87 33.28 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -178.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 22' ' ' THR . . . . . . . . . . . . . 81.8 m -102.53 -38.58 7.48 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 117.604 0.702 . . . . 0.0 111.1 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 23' ' ' LYS . . . . . . . . . . . . . 87.8 mttt -63.87 -46.28 85.65 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.13 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 24' ' ' LYS . . . . . . . . . . . . . 67.2 tttt -64.53 -42.15 95.92 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 110.062 -0.348 . . . . 0.0 110.062 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 25' ' ' LEU . . . . . 0.424 ' C ' HD23 ' F' ' 25' ' ' LEU . 6.8 tt -60.44 -22.72 63.75 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.99 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 26' ' ' GLY . . . . . . . . . . . . . . . -68.06 -51.61 32.76 Favored Glycine 0 C--N 1.334 0.464 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 27' ' ' SER . . . . . . . . . . . . . 66.7 m -63.0 -41.48 99.59 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.668 179.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 28' ' ' ILE . . . . . . . . . . . . . 90.3 mt -63.06 -47.02 94.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.456 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' F' ' 33' ' ' GLY . . . -64.27 -50.79 57.79 Favored Glycine 0 CA--C 1.528 0.87 0 C-N-CA 120.235 -0.983 . . . . 0.0 111.282 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 30' ' ' SER . . . . . . . . . . . . . 16.2 m -60.61 -38.27 84.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 117.239 0.519 . . . . 0.0 110.376 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 31' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -63.98 -43.74 94.83 Favored 'General case' 0 C--N 1.333 -0.148 0 C-N-CA 120.661 -0.415 . . . . 0.0 110.011 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 32' ' ' LEU . . . . . . . . . . . . . 75.4 mt -84.18 -12.15 55.38 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.339 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' F' ' 29' ' ' GLY . . . -84.89 6.02 80.25 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.47 -37.28 87.0 Favored 'General case' 0 C--N 1.332 -0.156 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.685 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 35' ' ' SER . . . . . . . . . . . . . 37.8 t -65.77 -36.53 83.8 Favored 'General case' 0 C--O 1.222 -0.38 0 CA-C-O 120.788 0.328 . . . . 0.0 110.794 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 36' ' ' ILE . . . . . . . . . . . . . 85.1 mt -61.42 -41.18 88.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 37' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -55.78 -37.51 68.66 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.52 -0.472 . . . . 0.0 109.91 -179.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.83 -41.92 80.93 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.593 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 39' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -60.55 -47.09 87.7 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.053 -0.659 . . . . 0.0 109.651 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 40' ' ' LYS . . . . . . . . . . . . . 55.8 tttp -58.45 -46.17 87.11 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.904 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 41' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -61.98 -50.85 70.44 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.365 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.57 -44.01 84.96 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 120.082 -0.647 . . . . 0.0 111.416 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 43' ' ' MET . . . . . . . . . . . . . 20.3 mtm -77.14 14.35 0.92 Allowed 'General case' 0 C--N 1.333 -0.15 0 O-C-N 122.073 -0.392 . . . . 0.0 110.592 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 44' ' ' SER . . . . . . . . . . . . . 28.8 t -169.27 80.92 0.12 Allowed 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.727 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 45' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -61.81 -45.7 92.69 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.217 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 46' ' ' ASP . . . . . 0.483 ' CG ' ' H ' ' F' ' 47' ' ' GLU . 37.7 t70 -93.93 179.05 5.47 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 121.017 -0.273 . . . . 0.0 110.289 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 47' ' ' GLU . . . . . 0.483 ' H ' ' CG ' ' F' ' 46' ' ' ASP . 16.9 tp10 -173.18 125.16 0.45 Allowed Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 48' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.02 -19.54 26.45 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 121.824 1.683 . . . . 0.0 111.903 -179.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 49' ' ' LYS . . . . . . . . . . . . . 17.4 ptpt . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.748 -179.685 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 1' ' ' FME . . . . . 0.533 ' N ' ' SD ' ' G' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.91 166.16 30.45 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . 161.64 -78.96 0.16 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 4' ' ' ILE . . . . . . . . . . . . . 89.7 mt -99.57 112.92 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.681 0.277 . . . . 0.0 110.389 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 5' ' ' SER . . . . . 0.432 ' OG ' ' OE1' ' G' ' 8' ' ' GLN . 35.2 t -119.61 126.26 50.74 Favored 'General case' 0 C--O 1.223 -0.324 0 CA-C-O 121.581 0.705 . . . . 0.0 111.208 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 6' ' ' ILE . . . . . . . . . . . . . 12.1 tt -66.49 -34.22 68.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.113 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 7' ' ' TRP . . . . . . . . . . . . . 45.8 m95 -58.98 -29.12 66.97 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.612 -179.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 8' ' ' GLN . . . . . 0.56 ' N ' ' OE1' ' G' ' 8' ' ' GLN . 0.9 OUTLIER -59.52 -35.03 73.4 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.336 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' G' G ' 9' ' ' LEU . . . . . . . . . . . . . 96.1 mt -69.34 -38.75 78.3 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.609 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 10' ' ' LEU . . . . . . . . . . . . . 2.5 mt -60.59 -47.56 85.66 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 122.053 -0.404 . . . . 0.0 110.833 -179.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 11' ' ' ILE . . . . . . . . . . . . . 10.9 tt -65.1 -43.31 95.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.145 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 12' ' ' ILE . . . . . . . . . . . . . 40.4 mt -63.5 -44.34 98.72 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.076 0 C-N-CA 120.944 -0.303 . . . . 0.0 110.808 178.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.0 -39.76 90.95 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.294 -179.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 14' ' ' VAL . . . . . . . . . . . . . 25.1 t -60.14 -44.83 96.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 15' ' ' ILE . . . . . 0.514 ' O ' ' HG ' ' G' ' 19' ' ' LEU . 69.8 mt -61.41 -44.66 98.91 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.897 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.236 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 16' ' ' VAL . . . . . . . . . . . . . 60.1 t -58.53 -45.77 90.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.758 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 17' ' ' VAL . . . . . 0.581 ' O ' ' N ' ' G' ' 21' ' ' GLY . 92.0 t -63.18 -43.14 98.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.93 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 18' ' ' LEU . . . . . . . . . . . . . 93.9 mt -65.04 -46.21 82.23 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.039 -179.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 19' ' ' LEU . . . . . 0.551 HD12 HD13 ' H' ' 18' ' ' LEU . 52.5 mt -63.9 -42.43 97.43 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 120.724 -0.391 . . . . 0.0 110.345 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -88.55 -11.07 46.71 Favored 'General case' 0 N--CA 1.47 0.556 0 O-C-N 122.33 -0.231 . . . . 0.0 110.464 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 21' ' ' GLY . . . . . 0.581 ' N ' ' O ' ' G' ' 17' ' ' VAL . . . 73.85 176.75 34.44 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -178.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 22' ' ' THR . . . . . . . . . . . . . 18.9 m -102.36 -38.78 7.46 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 117.654 0.727 . . . . 0.0 110.945 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 23' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -63.81 -46.53 84.72 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 120.431 -0.508 . . . . 0.0 110.947 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 24' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -64.49 -41.86 96.2 Favored 'General case' 0 C--N 1.336 -0.015 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.09 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 25' ' ' LEU . . . . . 0.423 ' C ' HD23 ' G' ' 25' ' ' LEU . 7.0 tt -60.71 -22.6 64.13 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 120.529 -0.468 . . . . 0.0 110.888 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 26' ' ' GLY . . . . . . . . . . . . . . . -68.13 -51.32 34.06 Favored Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.596 -1.002 . . . . 0.0 110.596 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 27' ' ' SER . . . . . . . . . . . . . 78.2 p -63.03 -41.35 99.51 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 121.015 -0.274 . . . . 0.0 110.827 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 28' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.37 -46.72 94.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.695 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.4 ' O ' ' N ' ' G' ' 33' ' ' GLY . . . -64.2 -50.83 57.69 Favored Glycine 0 CA--C 1.529 0.931 0 C-N-CA 120.424 -0.894 . . . . 0.0 111.189 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 30' ' ' SER . . . . . . . . . . . . . 22.5 m -60.83 -38.43 85.44 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 117.255 0.528 . . . . 0.0 110.353 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 31' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -63.6 -43.73 96.07 Favored 'General case' 0 C--N 1.332 -0.17 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.121 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 32' ' ' LEU . . . . . . . . . . . . . 74.7 mt -84.52 -11.57 55.84 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.296 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' G' ' 29' ' ' GLY . . . -85.34 6.4 79.96 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.111 -0.795 . . . . 0.0 111.111 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 34' ' ' ALA . . . . . 0.489 ' O ' ' HG3' ' G' ' 37' ' ' LYS . . . -64.35 -37.49 87.68 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 117.148 0.474 . . . . 0.0 110.841 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -65.86 -36.28 83.01 Favored 'General case' 0 C--O 1.226 -0.141 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.79 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 36' ' ' ILE . . . . . . . . . . . . . 82.0 mt -61.77 -40.64 87.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 37' ' ' LYS . . . . . 0.489 ' HG3' ' O ' ' G' ' 34' ' ' ALA . 0.0 OUTLIER -55.94 -37.48 69.04 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.879 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . 0.451 ' N ' ' HG3' ' G' ' 37' ' ' LYS . . . -68.89 -41.98 80.27 Favored Glycine 0 CA--C 1.524 0.597 0 C-N-CA 120.579 -0.82 . . . . 0.0 111.647 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 39' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -60.56 -46.79 88.88 Favored 'General case' 0 C--N 1.334 -0.088 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.69 179.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 40' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -58.73 -45.84 88.73 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.121 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 41' ' ' LYS . . . . . . . . . . . . . 47.1 mmtt -61.83 -51.13 69.48 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.266 -179.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.73 -43.78 85.53 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.381 -179.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 43' ' ' MET . . . . . 0.425 ' O ' ' OD1' ' G' ' 46' ' ' ASP . 3.4 mtm -77.32 15.21 0.79 Allowed 'General case' 0 N--CA 1.456 -0.167 0 O-C-N 122.075 -0.391 . . . . 0.0 110.405 179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 44' ' ' SER . . . . . . . . . . . . . 84.0 p -71.78 -10.93 60.5 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 111.596 0.221 . . . . 0.0 111.596 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 45' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -61.54 -45.02 95.95 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.841 -0.344 . . . . 0.0 111.11 -179.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 46' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' G' ' 43' ' ' MET . 41.4 p30 -90.02 45.94 1.31 Allowed 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 121.216 -0.193 . . . . 0.0 110.772 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 47' ' ' GLU . . . . . . . . . . . . . 73.5 mt-10 -151.71 94.48 3.37 Favored Pre-proline 0 CA--C 1.536 0.406 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 48' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -53.34 140.81 62.19 Favored 'Trans proline' 0 N--CA 1.498 1.764 0 C-N-CA 122.204 1.936 . . . . 0.0 112.216 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 49' ' ' LYS . . . . . . . . . . . . . 27.5 mmtp . . . . . 0 C--N 1.327 -0.385 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.344 -178.931 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.15 161.72 29.4 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 111.061 -0.815 . . . . 0.0 111.061 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -163.29 149.75 17.69 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 4' ' ' ILE . . . . . . . . . . . . . 50.6 mt 38.99 67.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 120.802 0.334 . . . . 0.0 110.317 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 5' ' ' SER . . . . . . . . . . . . . 18.3 t -117.2 129.67 56.09 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-O 121.301 0.572 . . . . 0.0 111.736 -178.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 6' ' ' ILE . . . . . . . . . . . . . 14.3 tt -65.68 -32.32 57.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.481 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 7' ' ' TRP . . . . . . . . . . . . . 46.1 m95 -56.92 -28.62 62.24 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.128 -1.397 . . . . 0.0 110.431 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 8' ' ' GLN . . . . . . . . . . . . . 52.9 mt-30 -60.04 -34.72 73.77 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.389 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 9' ' ' LEU . . . . . . . . . . . . . 36.2 mt -69.76 -38.49 76.78 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.534 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 10' ' ' LEU . . . . . . . . . . . . . 2.9 mt -60.76 -47.66 85.31 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.376 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 11' ' ' ILE . . . . . . . . . . . . . 10.5 tt -64.92 -43.39 96.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.111 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 12' ' ' ILE . . . . . . . . . . . . . 40.7 mt -63.83 -43.87 97.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.791 179.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.83 -40.32 92.34 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.077 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 14' ' ' VAL . . . . . . . . . . . . . 24.8 t -59.77 -45.42 94.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 15' ' ' ILE . . . . . 0.56 ' O ' ' HG ' ' H' ' 19' ' ' LEU . 74.2 mt -61.12 -44.61 98.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.64 0 C-N-CA 120.375 -0.53 . . . . 0.0 110.167 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 16' ' ' VAL . . . . . . . . . . . . . 41.8 t -58.69 -45.42 90.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 O-C-N 121.957 -0.464 . . . . 0.0 110.987 179.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 17' ' ' VAL . . . . . 0.576 ' O ' ' N ' ' H' ' 21' ' ' GLY . 84.0 t -63.53 -42.82 97.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.942 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 18' ' ' LEU . . . . . 0.551 HD13 HD12 ' G' ' 19' ' ' LEU . 4.8 mt -65.56 -45.83 81.83 Favored 'General case' 0 N--CA 1.465 0.285 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.009 -179.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 19' ' ' LEU . . . . . 0.56 ' HG ' ' O ' ' H' ' 15' ' ' ILE . 28.9 mt -64.04 -42.16 97.15 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.518 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -89.05 -10.81 46.08 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 21' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' H' ' 17' ' ' VAL . . . 73.72 176.66 33.82 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.303 -1.519 . . . . 0.0 109.303 -178.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 22' ' ' THR . . . . . . . . . . . . . 29.6 m -102.05 -38.67 7.64 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 117.408 0.604 . . . . 0.0 111.289 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 23' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -63.89 -46.49 84.64 Favored 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 120.523 -0.471 . . . . 0.0 110.781 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 24' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -64.31 -42.06 96.52 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.027 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 25' ' ' LEU . . . . . 0.409 HD23 ' C ' ' H' ' 25' ' ' LEU . 8.0 tt -60.83 -22.75 64.51 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.566 -0.454 . . . . 0.0 110.874 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.93 -51.32 35.24 Favored Glycine 0 C--N 1.334 0.436 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 27' ' ' SER . . . . . . . . . . . . . 78.2 p -63.12 -41.29 99.32 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.819 179.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 28' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.28 -46.89 94.47 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 C-N-CA 120.498 -0.481 . . . . 0.0 110.699 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' H' ' 33' ' ' GLY . . . -64.32 -50.54 59.18 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 120.16 -1.019 . . . . 0.0 111.437 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 30' ' ' SER . . . . . . . . . . . . . 15.8 m -61.07 -37.98 84.59 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 117.322 0.561 . . . . 0.0 110.455 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 31' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -64.01 -43.62 95.06 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.262 179.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -84.28 -11.86 55.69 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.391 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' H' ' 29' ' ' GLY . . . -85.24 6.59 79.09 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.41 -37.35 87.21 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.744 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -65.85 -36.68 84.13 Favored 'General case' 0 C--O 1.222 -0.357 0 C-N-CA 120.985 -0.286 . . . . 0.0 110.491 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 36' ' ' ILE . . . . . . . . . . . . . 90.2 mt -61.4 -41.01 88.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 37' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -55.49 -37.82 68.33 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.911 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.9 -41.69 81.37 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 120.251 -0.975 . . . . 0.0 111.592 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 39' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -60.99 -46.62 90.02 Favored 'General case' 0 C--N 1.333 -0.126 0 C-N-CA 119.912 -0.715 . . . . 0.0 109.518 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 40' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -58.71 -46.09 88.1 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.034 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 41' ' ' LYS . . . . . . . . . . . . . 27.5 tptp -61.86 -50.89 70.44 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.298 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.71 -43.8 85.48 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 120.017 -0.673 . . . . 0.0 111.377 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 43' ' ' MET . . . . . . . . . . . . . 19.7 mtm -77.26 14.46 0.93 Allowed 'General case' 0 N--CA 1.463 0.212 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.275 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 44' ' ' SER . . . . . . . . . . . . . 22.6 t -138.9 44.32 2.05 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 120.727 0.299 . . . . 0.0 110.851 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 45' ' ' ASP . . . . . 0.585 ' C ' ' H ' ' H' ' 47' ' ' GLU . 40.7 t0 -62.72 -43.09 99.71 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.673 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 46' ' ' ASP . . . . . . . . . . . . . 41.2 t0 62.95 -25.94 0.06 Allowed 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 47' ' ' GLU . . . . . 0.585 ' H ' ' C ' ' H' ' 45' ' ' ASP . 7.1 pt-20 -175.62 158.76 1.98 Allowed Pre-proline 0 CA--C 1.537 0.474 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 48' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.23 -39.27 81.29 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 121.689 1.593 . . . . 0.0 112.185 178.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 49' ' ' LYS . . . . . . . . . . . . . 66.1 tttm . . . . . 0 C--N 1.331 -0.21 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.612 -179.98 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.7 -121.64 0.86 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 3' ' ' GLY . . . . . . . . . . . . . . . 92.14 -6.89 78.83 Favored Glycine 0 N--CA 1.467 0.714 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 4' ' ' ILE . . . . . 0.877 HD13 ' H ' ' I' ' 4' ' ' ILE . 0.1 OUTLIER -130.83 166.59 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 -179.569 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' I' I ' 5' ' ' SER . . . . . 0.585 ' OG ' ' NE2' ' I' ' 8' ' ' GLN . 0.3 OUTLIER -138.81 82.29 1.89 Allowed 'General case' 0 CA--C 1.533 0.311 0 CA-C-O 121.473 0.654 . . . . 0.0 110.639 179.536 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' I' I ' 6' ' ' ILE . . . . . . . . . . . . . 34.2 mm -71.36 -43.45 73.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.395 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 7' ' ' TRP . . . . . . . . . . . . . 20.5 m95 -54.92 -29.04 55.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.725 -178.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 8' ' ' GLN . . . . . 0.67 ' N ' ' NE2' ' I' ' 8' ' ' GLN . 0.4 OUTLIER -59.95 -34.74 73.67 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.379 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' I' I ' 9' ' ' LEU . . . . . . . . . . . . . 92.3 mt -69.62 -38.59 77.3 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.588 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 10' ' ' LEU . . . . . 0.532 ' N ' HD12 ' I' ' 10' ' ' LEU . 9.6 mp -60.82 -47.33 86.82 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.77 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 11' ' ' ILE . . . . . 0.483 HG22 ' O ' ' I' ' 8' ' ' GLN . 9.5 tt -64.95 -43.65 96.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 C-N-CA 120.749 -0.38 . . . . 0.0 109.984 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 12' ' ' ILE . . . . . 0.598 ' CG2' HG11 ' A' ' 14' ' ' VAL . 1.4 mm -63.59 -43.94 98.4 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.727 179.171 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.13 -40.03 92.27 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.208 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 14' ' ' VAL . . . . . . . . . . . . . 22.6 t -60.01 -44.97 95.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 15' ' ' ILE . . . . . 0.506 ' O ' ' HG ' ' I' ' 19' ' ' LEU . 7.0 mm -61.01 -44.8 98.98 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.702 0 C-N-CA 120.653 -0.419 . . . . 0.0 110.188 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 16' ' ' VAL . . . . . . . . . . . . . 49.5 t -58.69 -45.49 90.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 C-N-CA 120.456 -0.498 . . . . 0.0 111.09 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 17' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' I' ' 21' ' ' GLY . 91.9 t -63.36 -42.87 97.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.947 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 18' ' ' LEU . . . . . 0.401 HD13 HD12 ' H' ' 19' ' ' LEU . 10.3 mt -65.34 -46.09 81.64 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 119.974 -0.69 . . . . 0.0 110.94 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 19' ' ' LEU . . . . . 0.506 ' HG ' ' O ' ' I' ' 15' ' ' ILE . 48.3 mt -63.95 -42.43 97.3 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 120.839 -0.344 . . . . 0.0 110.278 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 32.6 m-85 -88.82 -10.71 47.1 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.7 0.286 . . . . 0.0 110.583 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 21' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' I' ' 17' ' ' VAL . . . 73.82 176.51 33.9 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 22' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.19 -38.77 7.54 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 117.536 0.668 . . . . 0.0 110.908 -179.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 23' ' ' LYS . . . . . . . . . . . . . 87.1 mttt -64.09 -46.71 83.06 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.531 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 24' ' ' LYS . . . . . . . . . . . . . 16.9 tptp -64.35 -42.08 96.42 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 110.005 -0.369 . . . . 0.0 110.005 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 25' ' ' LEU . . . . . . . . . . . . . 6.5 tt -60.73 -22.48 64.04 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.801 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 26' ' ' GLY . . . . . . . . . . . . . . . -68.05 -51.42 33.99 Favored Glycine 0 C--N 1.334 0.465 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 27' ' ' SER . . . . . . . . . . . . . 42.9 m -62.89 -41.76 99.53 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.666 179.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 28' ' ' ILE . . . . . . . . . . . . . 91.5 mt -63.07 -46.92 94.89 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 C-N-CA 120.586 -0.445 . . . . 0.0 110.546 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' I' ' 33' ' ' GLY . . . -64.03 -51.26 54.73 Favored Glycine 0 CA--C 1.53 1.001 0 C-N-CA 120.549 -0.834 . . . . 0.0 111.193 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 30' ' ' SER . . . . . . . . . . . . . 77.4 p -60.46 -38.42 84.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 117.068 0.434 . . . . 0.0 110.298 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 31' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -63.91 -43.53 95.66 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.185 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 32' ' ' LEU . . . . . . . . . . . . . 71.2 mt -84.32 -11.86 55.62 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.489 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' I' ' 29' ' ' GLY . . . -85.21 6.68 78.7 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.39 -37.63 88.19 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 117.006 0.403 . . . . 0.0 110.712 -179.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -65.67 -36.53 83.93 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.901 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 36' ' ' ILE . . . . . . . . . . . . . 86.6 mt -61.56 -40.98 88.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 37' ' ' LYS . . . . . . . . . . . . . 55.0 mtpt -55.64 -37.65 68.5 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.384 -0.526 . . . . 0.0 110.074 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.59 -42.09 81.94 Favored Glycine 0 C--N 1.334 0.434 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.634 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 39' ' ' PHE . . . . . 0.427 ' CD1' ' C ' ' I' ' 39' ' ' PHE . 18.7 t80 -60.62 -46.93 88.42 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.146 -0.622 . . . . 0.0 109.554 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 40' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -58.72 -46.0 88.32 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.889 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 41' ' ' LYS . . . . . . . . . . . . . 66.2 tttm -61.8 -51.04 69.92 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.24 -179.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.65 -43.84 85.2 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.404 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 43' ' ' MET . . . . . . . . . . . . . 16.3 ttp -77.14 17.68 0.44 Allowed 'General case' 0 C--O 1.233 0.211 0 C-N-CA 120.829 -0.348 . . . . 0.0 110.442 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 44' ' ' SER . . . . . . . . . . . . . 17.9 m -136.6 -4.89 2.01 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 178.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 45' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -64.61 -46.68 81.6 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.064 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 46' ' ' ASP . . . . . 0.536 ' OD1' ' N ' ' I' ' 47' ' ' GLU . 1.2 p30 -40.41 -51.94 2.79 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 120.896 -0.322 . . . . 0.0 111.142 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 47' ' ' GLU . . . . . 0.536 ' N ' ' OD1' ' I' ' 46' ' ' ASP . 2.1 tm-20 -178.41 117.69 0.24 Allowed Pre-proline 0 CA--C 1.546 0.82 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 48' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -74.69 -14.38 21.93 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 121.672 1.581 . . . . 0.0 112.022 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 49' ' ' LYS . . . . . . . . . . . . . 99.1 mttt . . . . . 0 N--CA 1.465 0.288 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.502 -179.566 . . . . . . . . 0 0 . 1 stop_ save_